10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the Quarterly Period Ended March 31, 2013

AMSURG CORP.

(Exact Name of Registrant as Specified in its Charter)

Tennessee	000-22217	62-1493316
(State or Other Jurisdiction of Incorporation)	(Commission  File Number)	(I.R.S. Employer  Identification No.)
20 Burton Hills Boulevard
Nashville, Tennessee		37215
(Address of Principal Executive Offices)		(Zip Code)

 (615) 665-1283

(Registrant’s Telephone Number, Including Area Code)

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]                   No [  ]

        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X]                   No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.   (Check one):

                                Large accelerated filer  [X]                                      Accelerated filer                  [  ]

Non-accelerated filer    [   ]                                     Smaller reporting company [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]                    No [X]

As of May 6, 2013 there were outstanding 31,992,677 shares of the registrant’s Common Stock, no par value.

Table of Contents to Form 10-Q for the Three Months Ended March 31, 2013
Part I
	Item 1.	Financial Statements	1
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
	Item 4.	Controls and Procedures	26
Part II
	Item 1.	Legal Proceedings	27
	Item 1A.	Risk Factors	27
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
	Item 3.	Defaults Upon Senior Securities	27
	Item 4.	Mine Safety Disclosures	27
	Item 5.	Other Information	27
	Item 6.	Exhibits	27
	Signature		28

i

Part I

Item 1.  Financial Statements

AmSurg Corp.

Consolidated Balance Sheets

March 31, 2013 (unaudited) and December 31, 2012

(Dollars in thousands)

				March 31,		December 31,
				2013		2012
Assets
Current assets:
	Cash and cash equivalents			$	42,413	$	46,398
	Accounts receivable, net of allowance of $24,276 and $22,379, respectively				101,503		96,752
	Supplies inventory				18,106		18,406
	Deferred income taxes				978		3,088
	Prepaid and other current assets				30,142		27,537
			Total current assets		193,142		192,181
Property and equipment, net					163,189		166,612
Investments in unconsolidated affiliates and long-term notes receivable					16,876		11,274
Goodwill					1,647,180		1,652,002
Intangible assets, net					21,985		22,517
			Total assets	$	2,042,372	$	2,044,586
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	19,942	$	17,407
	Accounts payable				19,744		23,509
	Accrued salaries and benefits				23,011		29,251
	Other accrued liabilities				15,237		14,246
			Total current liabilities		77,934		84,413
Long-term debt					603,409		620,705
Deferred income taxes					147,125		137,648
Other long-term liabilities					26,677		25,972
Commitments and contingencies
Noncontrolling interests – redeemable					175,709		175,382
Preferred stock, no par value, 5,000,000 shares authorized, no shares issued or outstanding					-		-
Equity:
	Common stock, no par value, 70,000,000 shares authorized, 31,898,868 and 31,941,441
		shares outstanding, respectively			175,532		183,867
	Retained earnings				523,432		505,621
			Total AmSurg Corp. equity		698,964		689,488
			Noncontrolling interests – non-redeemable		312,554		310,978
			Total equity		1,011,518		1,000,466
			Total liabilities and equity	$	2,042,372	$	2,044,586

See accompanying notes to the unaudited consolidated financial statements.

1

Item 1. Financial Statements – (continued)

AmSurg Corp.

Consolidated Statements of Earnings and Comprehensive Income (unaudited)

Three Months Ended March 31, 2013 and 2012

(In thousands, except earnings per share) 

					Three Months Ended
					March 31,
					2013		2012
Revenues					$	260,061	$	228,899
Operating expenses:
	Salaries and benefits					81,581		72,115
	Supply cost					37,644		32,097
	Other operating expenses					53,261		47,132
	Depreciation and amortization					8,082		7,341
				Total operating expenses		180,568		158,685
Gain on deconsolidation						2,237		-
Equity in earnings of unconsolidated affiliates						402		395
				Operating income		82,132		70,609
Interest expense						7,544		4,267
	Earnings from continuing operations before income taxes					74,588		66,342
Income tax expense						12,315		10,816
	Net earnings from continuing operations					62,273		55,526
Discontinued operations:
	Earnings from operations of discontinued interests in surgery centers,
		net of income tax				-		306
	Loss on disposal of discontinued interests in surgery centers,
		net of income tax				-		(893)
			Net loss from discontinued operations			-		(587)
	Net earnings and comprehensive income					62,273		54,939
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					44,462		39,972
	Net earnings from discontinued operations					-		191
			Total net earnings attributable to noncontrolling interests			44,462		40,163
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders		$	17,811	$	14,776
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	17,811	$	15,554
	Discontinued operations, net of income tax					-		(778)
			Net earnings and comprehensive income attributable to AmSurg Corp. common shareholders		$	17,811	$	14,776
Earnings per share-basic:
	Net earnings from continuing operations attributable to
		AmSurg Corp. common shareholders			$	0.57	$	0.51
	Net loss from discontinued operations attributable to
		AmSurg Corp. common shareholders				-		(0.03)
			Net earnings attributable to AmSurg Corp. common shareholders		$	0.57	$	0.48
Earnings per share-diluted:
	Net earnings from continuing operations attributable to
		AmSurg Corp. common shareholders			$	0.56	$	0.50
	Net loss from discontinued operations attributable to
		AmSurg Corp. common shareholders				-		(0.02)
			Net earnings attributable to AmSurg Corp. common shareholders		$	0.56	$	0.47
Weighted average number of shares and share equivalents outstanding:
	Basic					31,217		30,619
	Diluted					31,881		31,401

See accompanying notes to the unaudited consolidated financial statements.

2

Item 1. Financial Statements – (continued)

AmSurg Corp.

Consolidated Statements of Changes in Equity (unaudited)

Three Months Ended March 31, 2013 and 2012

(In thousands) 

			AmSurg Corp. Shareholders
												Non-
								Non-				Controlling
								Controlling				Interests –
								Interests –		Total		Redeemable
			Common Stock			Retained		Non-		Equity		(Temporary		Net
			Shares	Amount		Earnings		Redeemable		(Permanent)		Equity)		Earnings
Balance at December 31, 2012			31,941	$	183,867	$	505,621	$	310,978	$	1,000,466	$	175,382
	Issuance of restricted common stock		263		-		-		-		-		-
	Cancellation of restricted common stock		(14)		-		-		-		-		-
	Stock options exercised		237		5,691		-		-		5,691		-
	Stock repurchased		(528)		(16,758)		-		-		(16,758)		-
	Share-based compensation		-		2,050		-		-		2,050		-
	Tax benefit related to exercise of stock options		-		1,630		-		-		1,630		-
	Net earnings		-		-		17,811		12,232		30,043		32,230	$	62,273
	Distributions to noncontrolling
		interests, net of capital contributions	-		-		-		(11,891)		(11,891)		(31,823)
	Purchase of noncontrolling interest		-		(304)		-		(133)		(437)		(316)
	Sale of noncontrolling interest		-		(644)		-		1,419		775		236
	Acquisitions and other transactions
		impacting noncontrolling interests	-		-		-		266		266		-
	Disposals and other transactions
		impacting noncontrolling interests	-		-		-		(317)		(317)		-
Balance at March 31, 2013			31,899	$	175,532	$	523,432	$	312,554	$	1,011,518	$	175,709
Balance at January 1, 2012			31,284	$	173,187	$	443,058	$	132,222	$	748,467	$	170,636
	Issuance of restricted common stock		255		-		-		-		-		-
	Stock options exercised		111		2,521		-		-		2,521		-
	Stock repurchased		(109)		(2,823)		-		-		(2,823)		-
	Share-based compensation		-		1,792		-		-		1,792		-
	Tax benefit related to exercise of stock options		-		198		-		-		198		-
	Net earnings		-		-		14,776		6,062		20,838		34,101	$	54,939
	Distributions to noncontrolling
		interests, net of capital contributions	-		-		-		(6,434)		(6,434)		(32,546)
	Sale of noncontrolling interest		-		(1,587)		-		1,728		141		-
	Acquisitions and other transactions
		impacting noncontrolling interests	-		-		-		2,223		2,223		2,467
	Disposals and other transactions
		impacting noncontrolling interests	-		(369)		-		-		(369)		176
Balance at March 31, 2012			31,541	$	172,919	$	457,834	$	135,801	$	766,554	$	174,834

See accompanying notes to the unaudited consolidated financial statements.

3

Item 1. Financial Statements – (continued)

AmSurg Corp.

Consolidated Statements of Cash Flows (unaudited)

Three Months Ended March 31, 2013 and 2012

(In thousands) 

							Three Months Ended
							March 31,
							2013		2012
Cash flows from operating activities:
	Net earnings						$	62,273	$	54,939
	Adjustments to reconcile net earnings to net cash flows provided by
		operating activities:
			Depreciation and amortization					8,082		7,341
			Net loss on sale of long-lived assets					-		599
			Gain on deconsolidation					(2,237)		-
			Share-based compensation					2,050		1,792
			Excess tax benefit from share-based compensation					(288)		(79)
			Deferred income taxes					12,929		8,722
			Equity in earnings of unconsolidated affiliates					(402)		(395)
			Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and
				dispositions, due to changes in:
					Accounts receivable, net			(1,705)		(1,119)
					Supplies inventory			(201)		177
					Prepaid and other current assets			17		(633)
					Accounts payable			(3,040)		(1,693)
					Accrued expenses and other liabilities			(4,101)		(985)
					Other, net			488		479
						Net cash flows provided by operating activities		73,865		69,145
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions							(252)		(9,857)
	Acquisition of property and equipment							(6,110)		(6,046)
						Net cash flows used in investing activities		(6,362)		(15,903)
Cash flows from financing activities:
	Proceeds from long-term borrowings							30,870		19,600
	Repayment on long-term borrowings							(48,211)		(30,877)
	Distributions to noncontrolling interests							(43,914)		(39,009)
	Proceeds from issuance of common stock upon exercise of stock options							5,691		2,521
	Repurchase of common stock							(16,758)		(2,823)
	Capital contributions and ownership transactions by noncontrolling interests							559		869
	Excess tax benefit from share-based compensation							288		79
	Financing cost incurred							(13)		-
						Net cash flows used in financing activities		(71,488)		(49,640)
Net (decrease) increase in cash and cash equivalents								(3,985)		3,602
Cash and cash equivalents, beginning of period								46,398		40,718
Cash and cash equivalents, end of period							$	42,413	$	44,320

See accompanying notes to the unaudited consolidated financial statements.

4

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements

(1)  Basis of Presentation          

AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”).  The Company does not have an ownership interest in a limited partnership or LLC greater than 51% which it does not consolidate.  The Company does have an ownership interest of less than 51% in seven limited partnerships and LLCs, three of which it consolidates as the Company has substantive participation rights and four of which it does not consolidate as the Company’s rights are limited to protective rights only.  The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated limited partnerships and LLCs.  Consolidation of such limited partnerships and LLCs is necessary as the Company’s wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the limited partnerships and LLCs, and have control of the entities.  The responsibilities of the Company’s noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests.  Intercompany profits, transactions and balances have been eliminated.  All limited partnerships and LLCs and noncontrolling partners are referred to herein as partnerships and partners, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity.  However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required.  Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the face of the consolidated statements of income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value.  Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

As further described in note 11, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company’s partnerships.  While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2013, the occurrence of such regulatory changes is outside the control of the Company.  As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests.  The partners of the Company’s center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax.  Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings.  However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense.  In addition, distributions from the partnerships are made to both the Company’s wholly owned subsidiaries and the partners on a pre-tax basis.

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method.  These investments are included as investments in unconsolidated affiliates and long-term notes receivable in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings and comprehensive income.  The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

The Company operates in one reportable business segment, the ownership and operation of ambulatory surgery centers.

These unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X.  In the opinion of management, the unaudited interim financial statements contained in this report reflect all adjustments, consisting of only normal recurring accruals, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented.  The results of operations for any interim period are not necessarily indicative of results for the full year.

The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2012 Annual Report on Form 10-K. 

5

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

(2)  Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

The determination of contractual and bad debt allowances constitutes a significant estimate.  Some of the factors considered by management in determining the amount of such allowances are the historical trends of the centers’ cash collections and contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.  Accordingly, net accounts receivable at March 31, 2013 and December 31, 2012 reflect allowances for contractual adjustments of $281,290,000 and $216,363,000, respectively, and allowances for bad debt expense of $24,276,000 and $22,379,000, respectively.  The increase in the allowance for contractual adjustments as of March 31, 2013 is primarily the result of the centers acquired at the end of 2012 and increases in gross fee schedules at certain of the Company’s centers.  For the three months ended March 31, 2013 and 2012, bad debt expense was approximately $5,914,000 and $5,183,000, respectively, and is included in other operating expenses.

(3)  Revenue Recognition

Center revenues consist of billing for the use of the centers’ facilities (the “facility fee”) directly to the patient or third-party payor and, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by our centers.  Such revenues are recognized when the related surgical procedures are performed.  Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid.  During the three months ended March 31, 2013 and 2012, the Company derived approximately 25% and 27%, respectively, of its revenues from governmental healthcare programs, primarily Medicare and Medicare managed programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

(4)  Acquisitions and Investments in Unconsolidated Affiliates

As a significant part of its growth strategy, the Company primarily acquires controlling interests in centers.  The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination.  The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control.  The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination.  Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.  Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest.  Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.

During the three  months ended March 31, 2013, the Company entered into a transaction whereby it contributed cash plus a controlling interest in one center in exchange for a noncontrolling interest in an entity that controls the contributed center and one additional center after the completion of the transaction.  Management of the Company believes this structure will provide both economies of scale and potential future growth opportunities in the market.  As a result of the transaction, the Company recorded in the accompanying consolidated balance sheets the fair value of the noncontrolling interest in the entity which now controls the contributed centers of approximately $5,201,000 as a component of investments in unconsolidated affiliates and long term notes receivable.  The Company also recognized a gain on deconsolidation in the accompanying consolidated statements of earnings and comprehensive income of approximately $2,237,000.  Such gain was determined based on the difference between the fair value of the retained noncontrolling interest under the new ownership and operating structure and the carrying value of both the tangible and intangible assets of the entity immediately prior to the transaction.  The fair value of the retained noncontrolling interest was based on various estimates of the expected future earnings under likely scenarios which were weighted by the probability of each outcome using a range of expected probability of 5% to 30%.

During the three months ended March 31, 2012, the Company, through a wholly owned subsidiary, acquired a controlling interest in two centers, one of which was merged into an existing center. 

The aggregate amount paid for the centers acquired and for settlement of purchase price payable obligations during the three months ended March 31, 2013 and 2012 was approximately $252,000 and $9,857,000, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility.  The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model. 

6

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

At  December 31, 2012, the Company had contingent purchase price obligations of $2,744,000  related to the Company’s acquisition of 17 centers from National Surgical Care, Inc.  (“NSC”) on September 1, 2011.  The Company agreed to pay as additional consideration an amount up to $7,500,000 based on a multiple of the excess earnings over the targeted earnings of the acquired centers, if any, from the period of January 1, 2012 to December 31, 2012.  During the three months ended March 31, 2013, the Company paid NSC $2,744,000 as final settlement of the additional consideration due in accordance with the purchase agreement.

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed in the three months ended March 31, 2013 and 2012 are as follows (in thousands):

		Three Months Ended March 31,
		2013		2012
Accounts receivable		$	-	$	140
Supplies, inventory, prepaid and other current assets			-		74
Property and equipment			-		786
Goodwill			-		11,911
Accounts payable			-		(11)
Other accrued liabilities			-		(67)
	Total fair value		-		12,833
	Less:  Fair value attributable to noncontrolling interests		-		4,690
	Acquisition date fair value of total consideration transferred	$	-	$	8,143

Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market.  Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests in centers.  Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability.  The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets.  For the three months ended March 31, 2013 and 2012, respectively, approximately $0 and $7,579,000 of goodwill recorded was deductible for tax purposes.  In connection with the transactions discussed above, the Company incurred and expensed in other operating expenses approximately $35,000 and $52,000 in acquisition related costs, primarily attorney’s fees, for the three months ended March 31, 2013 and 2012, respectively. 

Revenues and net earnings included in the three months ended March 31, 2013 and 2012 associated with these acquisitions are as follows (in thousands):

		Three Months Ended March 31,
		2013		2012
Revenues		$	-	$	215
Net earnings			-		74
Less:  Net earnings attributable to noncontrolling interests			-		35
	Net earnings attributable to AmSurg Corp. common shareholders	$	-	$	39

7

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

The unaudited consolidated pro forma results for the three months ended March 31, 2013 and 2012, assuming all 2013 acquisitions had been consummated on January 1, 2012 and all 2012 acquisitions had been consummated on January 1, 2011, are as follows (in thousands, except per share data):  

			Three Months Ended
			March 31,
			2013		2012
Revenues			$	260,061	$	268,598
Net earnings				62,273		65,160
Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings from continuing operations			17,811		18,299
	Net earnings			17,811		17,521
	Net earnings from continuing operations per common share:
		Basic	$	0.57	$	0.60
		Diluted	$	0.56	$	0.58
	Net earnings:
		Basic	$	0.57	$	0.57
		Diluted	$	0.56	$	0.56
	Weighted average number of shares and share equivalents:
		Basic		31,217		30,619
		Diluted		31,881		31,401

(5)  Dispositions

The Company initiated the disposition of certain of its centers during 2012 due to management’s assessment of the limited growth opportunities at these centers as a result of certain market driven strategies.  Results of operations of the centers discontinued for the three months ended March 31, 2012 are as follows (in thousands):

	Three
	Months Ended
	March 31,
	2012
Net loss from discontinued operations	$	(587)
Net loss from discontinued operations attributable to AmSurg Corp.		(778)

The results of operations of discontinued centers in 2012 have been classified as discontinued operations in the 2012 presentation.  Results of operations of the discontinued surgery centers for the three months ended March 31, 2012 are as follows (in thousands):

	Three
	Months Ended
	March 31,
	2012
Revenues	$	2,085
Earnings before income taxes		397
Net earnings		306

8

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

(6)  Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2013 and 2012 are as follows (in thousands):

		Three Months Ended
		March 31,
		2013		2012
Balance, beginning of period		$	1,652,002	$	1,229,298
Goodwill acquired, including post acquisition adjustments			(2,702)		11,911
Goodwill disposed, including impact of deconsolidation transaction			(2,120)		(787)
	Balance, end of period	$	1,647,180	$	1,240,422

Amortizable intangible assets at March 31, 2013 and December 31, 2012 consisted of the following (in thousands):

		March 31, 2013						December 31, 2012
		Gross						Gross
		Carrying		Accumulated				Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
Deferred financing cost		$	14,536	$	(3,519)	$	11,017	$	14,523	$	(3,029)	$	11,494
Agreements, contracts and other intangible assets			3,448		(2,305)		1,143		3,448		(2,250)		1,198
	Total amortizable intangible assets	$	17,984	$	(5,824)	$	12,160	$	17,971	$	(5,279)	$	12,692

Amortization of intangible assets for the three months ended March 31, 2013 and 2012 was $545,000 and $314,000, respectively.  Estimated amortization of intangible assets for the remainder of 2013 and the following five years and thereafter is $1,753,000, $2,334,000, $2,333,000, $2,332,000, $1,514,000, $939,000 and $955,000, respectively.  The Company expects to recognize amortization of intangible assets over a weighted average period of 5.6 years.

At March 31, 2013and December 31, 2012, other non-amortizable intangible assets related to restrictive covenant arrangements were $9,825,000, respectively.

(7)Long-term Debt

Long-term debt at March 31, 2013 and December 31, 2012 was comprised of the following (in thousands):

		March 31,		December 31,
		2013		2012
Revolving credit agreement		$	267,200	$	279,780
Senior Unsecured Notes			250,000		250,000
Senior Secured Notes			75,000		75,000
Other debt			19,774		21,350
Capitalized lease arrangements			11,377		11,982
			623,351		638,112
Less current portion			19,942		17,407
	Long-term debt	$	603,409	$	620,705

9

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

a.     Credit Facility

On June 29, 2012, the Company amended its revolving credit agreement to increase the borrowing capacity and adjust the interest rate spreads.   On November 7, 2012, the Company further amended its revolving credit agreement to allow for the Company’s issuance of the 5.625% Senior Unsecured Notes (discussed below), which resulted in certain adjustments to the existing covenants. The revolving credit agreement, as amended, permits the Company to borrow up to $475,000,000 at an interest rate equal to, at the Company’s option, the base rate plus 0.50% to 1.25% or LIBOR plus 1.50% to 2.25%, or a combination thereof; provides for a fee of 0.20% to 0.40% of unused commitments; and contains certain covenants relating to the ratio of debt to operating performance measurements, interest coverage ratios and minimum net worth.  Borrowings under the revolving credit agreement mature in June 2017 and are secured primarily by a pledge of the stock of our wholly-owned subsidiaries and our partnership and membership interests in the limited partnerships and limited liability companies.  The Company was in compliance with the covenants contained in the revolving credit agreement at March 31, 2013.

b.     Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250,000,000 aggregate principal amount of 5.625% senior unsecured notes due 2020 (the “Senior Unsecured Notes”).  The net proceeds from the issuance of the Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s existing revolving credit agreement, creating capacity to fund future acquisitions.  The Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by certain of its existing and subsequently acquired or organized wholly owned domestic subsidiaries, (the “Guarantors”). The Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, beginning on May 30, 2013, and ending on the maturity date of November 30, 2020.

Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings.  On or after November 30, 2015, the Company may redeem the Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:

Period	Redemption Price
2015	104.219%
2016	102.813%
2017	101.406%
2018 and thereafter	100.000%

The Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock.  The Company was in compliance with the covenants contained in the indenture relating to the Senior Unsecured Notes at March 31, 2013.

In connection with the issuance of the Senior Unsecured Notes, the Company entered into a registration rights agreement, dated November 20, 2012 (the “Registration Rights Agreement”). Under the terms of the Registration Rights Agreement, the Company and the Guarantors agreed to use their commercially reasonable efforts to file an exchange offer registration statement with respect to the Senior Unsecured Notes with the Securities and Exchange Commission (the “SEC”) and consummate the exchange offer within 270 days from the date of the Registration Rights Agreement.  On May 2, 2013, the registration statement became effective, following which, the holders of the Senior Unsecured Notes have 20 business days to complete their exchange.

c.     Senior Secured Notes

The senior secured notes (the “Senior Secured Notes”) were issued on May 28, 2010, pursuant to a note purchase agreement, in the principal amount of $75,000,000 and are due May 28, 2020.  The Senior Secured Notes, which were originally issued with a stated interest rate of 6.04%, were amended on November 7, 2012 to allow for the Company’s issuance of the Senior Unsecured Notes, which resulted in an increase in the annual interest rate of 2% to 8.04%, and included certain other adjustments to the existing covenants.  The Senior Secured Notes are pari passu with the indebtedness under the Company’s revolving credit agreement and the Senior Unsecured Notes and require payment of principal beginning in August 2013.  The note purchase agreement governing the Senior Secured Notes contains covenants similar to the covenants in the revolving credit agreement and includes a make whole provision in the event of any prepayment of principle.  The Company was in compliance with the covenants contained in the note purchase agreement relating to the Senior Secured Notes at March 31, 2013.

10

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

(8)  Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability.  The inputs used by the Company to measure fair value are classified into the following fair value hierarchy:

Level 1:  Quoted prices in active markets for identical assets or liabilities.

Level 2:  Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3:  Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The Company adopted the updated guidance of the Financial Accounting Standards Board (“FASB”) related to fair value measurements and disclosures, which requires a reporting entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and to describe the reasons for the transfers. In addition, in the reconciliation for fair value measurements using significant unobservable inputs, or Level 3, a reporting entity should disclose separately information about purchases, sales, issuances and settlements. The updated guidance also requires that an entity should provide fair value measurement disclosures for each class of assets and liabilities and disclosures about the valuation techniques and inputs used to measure fair value for both recurring and non-recurring fair value measurements for Level 2 and Level 3 fair value measurements. The guidance was effective for the Company January 1, 2010, except for the disclosures about purchases, sales, issuances and settlements in the roll forward activity in Level 3 fair value measurements, which became effective for the Company January 1, 2011.  The Company adopted the additional guidance with respect to the roll forward activity in Level 3 fair value measurements on January 1, 2011.

In determining the fair value of assets and liabilities that are measured on a recurring basis at March 31, 2013 and December 31, 2012, with the exception of the contingent purchase price payable, the Company utilized Level 2 inputs to perform such measurements methods, which were commensurate with the market approach.  The Company utilized Level 3 inputs, which utilizes unobservable data, to measure the fair value of the contingent purchase price payable (in thousands):

		March 31,		December 31,
		2013		2012
Assets:
	Supplemental executive retirement savings plan investments - Level 2	$	11,239	$	8,804
Liabilities:
	Contingent purchase price payable - Level 3	$	-	$	2,744

The fair value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets, was determined using the calculated net asset values obtained from the plan administrator and observable inputs of similar public mutual fund investments.  The fair value of the contingent purchase price payable related to the centers acquired from NSC as of December 31, 2012, was determined utilizing the actual earnings of those centers during the earnout period, January 1, 2012 to December 31, 2012, in accordance with the purchase agreement.  During the three months ended March 31, 2013, the Company paid $2,744,000 as final settlement of the contingent purchase price payable using its revolving credit facility.  There were no transfers to or from Levels 1 and 2 during the three months ended March 31, 2013.

Cash and cash equivalents, receivables and payables are reflected in the financial statements at cost, which approximates fair value.  The fair value of fixed rate long-term debt, with a carrying value of $352,403,000, was $371,090,000 at March 31, 2013.  The fair value of variable rate long-term debt approximates its carrying value of $270,948,000 at March 31, 2013.  With the exception of the Company’s Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders.  The fair value of the Company’s Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

11

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

(9)  Shareholders’ Equity

a.   Common Stock

On October 20, 2010, the Company’s Board of Directors authorized a stock repurchase program for up to $40,000,000 of the Company’s shares of common stock to be purchased over the following 18 months. On April 24, 2012, the Board of Directors authorized a new stock purchase program for up to $40,000,000 of the Company’s shares of common stock through November 1, 2013. 

During the three months ended March 31, 2013, the Company purchased 438,668 shares of the Company’s common stock for approximately $13,943,000, at an average price of $31.76 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company’s stock incentive plans.  During the three months ended March 31, 2012, the Company purchased 61,149 shares of the Company’s common stock for approximately $1,560,000, at an average price of $25.49 per share.  In addition, during the three months ended March 31, 2013, and March 31, 2012, the Company repurchased 89,788 shares and 48,139 shares, respectively, of common stock to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements.

b.   Stock Incentive Plans

In May 2006, the Company adopted the AmSurg Corp. 2006 Stock Incentive Plan.  The Company also has options outstanding under the AmSurg Corp. 1997 Stock Incentive Plan, under which no additional options may be granted.  Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock.  At March 31, 2013, 2,760,250 shares were authorized for grant under the 2006 Stock Incentive Plan and 909,568 shares were available for future equity grants, including 747,456 shares available for issuance as restricted stock.  Restricted stock granted to outside directors prior to 2012 vests over a two year period and restricted stock granted to outside directors in 2012 vest over a one year period.  Restricted stock granted to outside directors is subject to certain holding restrictions.  Restricted stock granted to employees during 2010 and thereafter vests over four years in three equal installments beginning on the second anniversary of the date of grant.  Restricted stock granted to employees prior to 2010 vests at the end of four years from the date of grant.  In addition, shares held by the Company’s senior management are subject to certain holding restrictions.  The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date.

No options have been issued subsequent to 2008 and all outstanding options are fully vested.  Options were granted at market value on the date of the grant and vested over four years.  Outstanding options have a term of ten years from the date of grant. 

Other information pertaining to share-based activity during the three months ended March 31, 2013 and 2012 was as follows (in thousands):

	Three Months Ended
	March 31,
	2013		2012
Share-based compensation expense	$	2,050	$	1,792
Fair value of shares vested		9,182		5,948
Cash received from option exercises		5,691		2,521
Tax benefit from option exercises		288		79

As of March 31, 2013, the Company had total unrecognized compensation cost of approximately $12,754,000 related to non-vested awards, which the Company expects to recognize through 2017 and over a weighted average period of 1.3 years.

Average outstanding share-based awards to purchase approximately 75,624 shares of common stock that had an exercise price in excess of the average market price of the common stock during the three months ended March 31, 2012, were not included in the calculation of diluted securities options under the treasury method for purposes of determining diluted earnings per share due to their anti-dilutive impact. For the period ended March 31, 2013, there were no options that were anti-dilutive.

12

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

A summary of the status of non-vested restricted shares at March 31, 2013 and changes during the three months ended March 31, 2013 is as follows:

			Weighted
		Number	Average
		of	Grant
		Shares	Price
Non-vested shares at December 31, 2012		828,686	$	22.50
	Shares granted	263,140		31.18
	Shares vested	(292,809)		20.59
	Shares forfeited	(13,836)		22.66
Non-vested shares at March 31, 2013		785,181	$	26.12

A summary of stock option activity for the three months ended March 31, 2013 is summarized as follows:

					Weighted
					Average
			Weighted		Remaining
		Number	Average		Contractual
		of	Exercise		Term
		Shares	Price		(in years)
Outstanding at December 31, 2012		1,662,830	$	23.82	2.9
	Options exercised with total intrinsic value of $5,691,000	(236,579)		24.06
Outstanding at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0
Vested at March 31, 2013 with aggregate intrinsic value of  $14,059,000		1,426,251	$	23.78	3.0
Exercisable at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at March 31, 2013 exercised their options at the Company’s closing stock price on March 31, 2013.

13

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

c.   Earnings per Share

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

			Three Months Ended March 31,
						Per
			Earnings		Shares	Share
			(Numerator)		(Denominator)	Amount
2013:
Net earnings from continuing operations attributable to AmSurg Corp.
	per common share (basic)		$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares				-	664
	Net earnings from continuing operations attributable to AmSurg Corp.
		per common share (diluted)	$	17,811	31,881	$	0.56
Net earnings attributable to AmSurg Corp. per common share (basic)			$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares				-	664
	Net earnings attributable to AmSurg Corp.
		per common share (diluted)	$	17,811	31,881	$	0.56
2012:
Net earnings from continuing operations attributable to AmSurg Corp.
	per common share (basic)		$	15,554	30,619	$	0.51
Effect of dilutive securities options and non-vested shares				-	782
	Net earnings from continuing operations attributable to AmSurg Corp.
		per common share (diluted)	$	15,554	31,401	$	0.50
Net earnings attributable to AmSurg Corp. per common share (basic)			$	14,776	30,619	$	0.48
Effect of dilutive securities options and non-vested shares				-	782
	Net earnings attributable to AmSurg Corp.
		per common share (diluted)	$	14,776	31,401	$	0.47

(10)  Income Taxes

The Company files a consolidated federal income tax return.  Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes.  In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings and comprehensive income.  The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file U.S. federal and various state tax returns.  With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2009.

(11)  Commitments and Contingencies

The Company and its subsidiaries are insured with respect to medical malpractice risk on a claims-made basis.  The Company also maintains insurance for general liability, director and officer liability and property damage.  Certain policies are subject to deductibles.  In addition to the

14

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries.  Management is not aware of any claims against it or its subsidiaries which would have a material financial impact on the Company.

Certain of the Company’s wholly owned subsidiaries, as general partners in the limited partnerships, are responsible for all debts incurred but unpaid by the limited partnerships.  As manager of the operations of the limited partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.

In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships.  The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements.  The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2013. 

(12)  Supplemental Cash Flow Information

Supplemental cash flow information for the three months ended March 31, 2013 and 2012 is as follows (in thousands):

			Three Months Ended
			March 31,
			2013		2012
Cash paid during the period for:
	Interest		$	3,547	$	6,204
	Income taxes, net of refunds			69		1,778
Non-cash investing and financing activities:
	Decrease in accounts payable associated with acquisition of
		property and equipment		(675)		(392)
	Capital lease obligations			-		120
	Effect of acquisitions and related transactions:
		Assets acquired, net of cash and adjustments		-		12,911
		Liabilities assumed and noncontrolling interests		-		(4,768)

13.  Financial Information for the Company and Its Subsidiaries

In 2012, the Company issued the Senior Unsecured Notes in the aggregate principal amount of $250,000,000.  The Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by certain of its existing and subsequently acquired or organized wholly owned domestic subsidiaries.  The Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered."  The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

15

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

Consolidating Balance Sheet - March 31, 2013 (Dollars in thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	4,763	$	-	$	37,650	$	-	$	42,413
	Accounts receivable, net				-		-		101,503		-		101,503
	Supplies inventory				-		-		18,106		-		18,106
	Deferred income taxes				978		-		-		-		978
	Prepaid and other current assets				23,249		-		11,838		(4,945)		30,142
		Total current assets			28,990		-		169,097		(4,945)		193,142
Property and equipment, net					9,266		-		153,923		-		163,189
Investments in unconsolidated affiliates and long-term notes receivable					1,414,727		1,383,795		-		(2,781,646)		16,876
Goodwill and other intangible assets, net					20,837		-		1,148		1,647,180		1,669,165
			Total assets	$	1,473,820	$	1,383,795	$	324,168	$	(1,139,411)	$	2,042,372
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	8,629	$	-	$	11,313	$	-	$	19,942
	Accounts payable				1,024		-		22,853		(4,133)		19,744
	Other accrued liabilities				23,820		-		15,239		(811)		38,248
		Total current liabilities			33,473		-		49,405		(4,944)		77,934
Long-term debt					583,571		-		50,770		(30,932)		603,409
Deferred income taxes					147,125		-		-		-		147,125
Other long-term liabilities					10,687		-		15,990		-		26,677
Noncontrolling interests – redeemable					-		-		62,250		113,459		175,709
Equity:
		Total AmSurg Corp. equity			698,964		1,383,795		110,054		(1,493,849)		698,964
		Noncontrolling interests – non-redeemable			-		-		35,699		276,855		312,554
		Total equity			698,964		1,383,795		145,753		(1,216,994)		1,011,518
			Total liabilities and equity	$	1,473,820	$	1,383,795	$	324,168	$	(1,139,411)	$	2,042,372

Consolidating Balance Sheet - December 31, 2012 (Dollars in thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	7,259	$	-	$	39,139	$	-	$	46,398
	Accounts receivable, net				-		-		96,752		-		96,752
	Supplies inventory				-		-		18,406		-		18,406
	Deferred income taxes				3,088		-		-		-		3,088
	Prepaid and other current assets				19,342		-		13,160		(4,965)		27,537
		Total current assets			29,689		-		167,457		(4,965)		192,181
Property and equipment, net					9,199		-		157,413		-		166,612
Investments in unconsolidated affiliates and long-term notes receivable					1,413,061		1,381,596		-		(2,783,383)		11,274
Goodwill and other intangible assets, net					21,311		-		1,206		1,652,002		1,674,519
			Total assets	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	5,357	$	-	$	12,050	$	-	$	17,407
	Accounts payable				1,379		-		26,035		(3,905)		23,509
	Other accrued liabilities				29,380		-		15,177		(1,060)		43,497
		Total current liabilities			36,116		-		53,262		(4,965)		84,413
Long-term debt					599,423		-		52,747		(31,465)		620,705
Deferred income taxes					137,648		-		-		-		137,648
Other long-term liabilities					10,585		-		15,387		-		25,972
Noncontrolling interests – redeemable					-		-		61,939		113,443		175,382
Equity:
		Total AmSurg Corp. equity			689,488		1,381,596		108,412		(1,490,008)		689,488
		Noncontrolling interests – non-redeemable			-		-		34,329		276,649		310,978
		Total equity			689,488		1,381,596		142,741		(1,213,359)		1,000,466
			Total liabilities and equity	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586

16

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2013 (In thousands)
							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues					$	5,380	$	-	$	258,919	$	(4,238)	$	260,061
Operating expenses:
	Salaries and benefits					15,421		-		66,273		(113)		81,581
	Supply cost					-		-		37,644		-		37,644
	Other operating expenses					5,060		-		52,326		(4,125)		53,261
	Depreciation and amortization					772		-		7,310		-		8,082
		Total operating expenses				21,253		-		163,553		(4,238)		180,568
Gain on deconsolidation						2,237		2,237		-		(2,237)		2,237
Equity in earnings of unconsolidated affiliates						50,291		50,291		-		(100,180)		402
		Operating income				36,655		52,528		95,366		(102,417)		82,132
Interest expense						6,923		-		621		-		7,544
	Earnings from continuing operations before income taxes					29,732		52,528		94,745		(102,417)		74,588
Income tax expense						11,921		-		394		-		12,315
	Net earnings from continuing operations					17,811		52,528		94,351		(102,417)		62,273
	Net earnings from discontinued operations					-		-		-		-		-
		Net earnings and comprehensive income				17,811		52,528		94,351		(102,417)		62,273
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		44,462		-		44,462
	Net earnings from discontinued operations					-		-		-		-		-
		Total net earnings attributable to noncontrolling interests				-		-		44,462		-		44,462
			Net earnings and comprehensive income attributable
				to AmSurg Corp. common shareholders	$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811
	Discontinued operations, net of income tax					-		-		-		-		-
			Net earnings and comprehensive income attributable
				to AmSurg Corp. common shareholders	$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811

Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2012 (In thousands)
							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues					$	5,145	$	-	$	227,232	$	(3,478)	$	228,899
Operating expenses:
	Salaries and benefits					14,154		-		58,048		(87)		72,115
	Supply cost					-		-		32,097		-		32,097
	Other operating expenses					4,741		-		45,782		(3,391)		47,132
	Depreciation and amortization					657		-		6,684		-		7,341
		Total operating expenses				19,552		-		142,611		(3,478)		158,685
Equity in earnings of unconsolidated affiliates						44,243		44,243		-		(88,091)		395
		Operating income				29,836		44,243		84,621		(88,091)		70,609
Interest expense						3,709		-		558		-		4,267
	Earnings from continuing operations before income taxes					26,127		44,243		84,063		(88,091)		66,342
Income tax expense						10,396		-		420		-		10,816
	Net earnings from continuing operations					15,731		44,243		83,643		(88,091)		55,526
	Net earnings from discontinued operations					(955)		-		368		-		(587)
		Net earnings and comprehensive income				14,776		44,243		84,011		(88,091)		54,939
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		39,972		-		39,972
	Net earnings from discontinued operations					-		-		191		-		191
		Total net earnings attributable to noncontrolling interests				-		-		40,163		-		40,163
			Net earnings and comprehensive income attributable to
				AmSurg Corp. common shareholders	$	14,776	$	44,243	$	43,848	$	(88,091)	$	14,776
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	15,731	$	44,243	$	43,671	$	(88,091)	$	15,554
	Discontinued operations, net of income tax					(955)		-		177		-		(778)
			Net earnings and comprehensive income attributable to
				AmSurg Corp. common shareholders	$	14,776	$	44,243	$	43,848	$	(88,091)	$	14,776

17

Item 1. Financial Statements – (continued)

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements – (continued)

Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2013 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	23,940	$	49,577	$	99,411	$	(99,063)	$	73,865
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(242)		-		(10)		(252)
	Acquisition of property and equipment			(853)		-		(5,257)		-		(6,110)
		Net cash flows used in investing activities		(853)		(242)		(5,257)		(10)		(6,362)
Cash flows from financing activities:
	Proceeds from long-term borrowings			29,700		-		1,170		-		30,870
	Repayment on long-term borrowings			(45,024)		-		(3,187)		-		(48,211)
	Distributions to owners, including noncontrolling interests			-		(49,486)		(93,491)		99,063		(43,914)
	Changes in intercompany balances with affiliates, net			533		-		(533)		-		-
	Other financing activities, net			(10,792)		151		398		10		(10,233)
		Net cash flows provided by (used in) financing activities		(25,583)		(49,335)		(95,643)		99,073		(71,488)
Net increase (decrease) in cash and cash equivalents				(2,496)		-		(1,489)		-		(3,985)
Cash and cash equivalents, beginning of period				7,259		-		39,139		-		46,398
Cash and cash equivalents, end of period			$	4,763	$	-	$	37,650	$	-	$	42,413

Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2012 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	10,211	$	43,158	$	92,976	$	(77,200)	$	69,145
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(9,925)		-		68		(9,857)
	Acquisition of property and equipment			(751)		-		(5,295)		-		(6,046)
		Net cash flows used in investing activities		(751)		(9,925)		(5,295)		68		(15,903)
Cash flows from financing activities:
	Proceeds from long-term borrowings			19,600		-		-		-		19,600
	Repayment on long-term borrowings			(28,100)		-		(2,777)		-		(30,877)
	Distributions to owners, including noncontrolling interests			-		(34,042)		(82,167)		77,200		(39,009)
	Changes in intercompany balances with affiliates, net			(460)		-		460		-		-
	Other financing activities, net			(223)		809		128		(68)		646
		Net cash flows provided by (used in) financing activities		(9,183)		(33,233)		(84,356)		77,132		(49,640)
Net increase (decrease) in cash and cash equivalents				277		-		3,325		-		3,602
Cash and cash equivalents, beginning of period				8,530		-		32,188		-		40,718
Cash and cash equivalents, end of period			$	8,807	$	-	$	35,513	$	-	$	44,320

(14)  Subsequent Events

The Company assessed events occurring subsequent to March 31, 2013 for potential recognition and disclosure in the unaudited consolidated financial statements. In April 2013, the Company, through a wholly owned subsidiary, acquired a majority interest in a surgery center for a purchase price of approximately $11,400,000.  Other than as previously described, no events have occurred that would require adjustment to or disclosure in the unaudited consolidated financial statements.

18

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements                                                                        

This report contains certain forward-looking statements (all statements other than with respect to historical fact) within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby.  Investors are cautioned that all forward-looking statements involve known and unknown risks and uncertainties including, without limitation, those described in this report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and listed below in this report, some of which are beyond our control.  Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate.  Therefore there can be no assurance that the forward-looking statements included in this report will prove to be accurate.  Actual results could differ materially and adversely from those contemplated by any forward-looking statement.  In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved.  We undertake no obligation to publicly release any revisions to any forward-looking statements in this discussion to reflect events and circumstances occurring after the date hereof or to reflect unanticipated events.

Forward-looking statements and our liquidity, financial condition and results of operations, may be affected by the following risks and uncertainties and the other risks and uncertainties discussed in this report, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012 under “Item 1A. – Risk Factors”, as well as other unknown risks and uncertainties:

·the risk that payments from third-party payors, including government healthcare programs, may decrease or not increase as our costs increase;

·adverse developments affecting the medical practices of our physician partners;

·our ability to maintain favorable relations with our physician partners;

·our ability to compete for physician partners, managed care contracts, patients and strategic relationships;

·our ability to acquire and develop additional surgery centers on favorable terms;

·our ability to grow revenues by increasing procedure volume while maintaining operating margins and profitability at our existing centers;

·our ability to manage the growth in our business;

·our ability to obtain sufficient capital resources to complete acquisitions and develop new surgery centers;

·our ability to generate sufficient cash flow to service our indebtedness;

·adverse weather and other factors beyond our control that may affect our surgery centers;

·adverse impacts on our business associated with current and future economic conditions;

·our failure to comply with applicable laws and regulations;

·the risk of changes in legislation, regulations or regulatory interpretations that may negatively affect us;

·the risk of becoming subject to federal and state investigation;

·uncertainties regarding the impact of the Health Reform Law;

·the risk of regulatory changes that may obligate us to buy out the ownership interests of physicians who are minority owners of our surgery centers;

·potential liabilities associated with our status as a general partner of limited partnerships;

·liabilities for claims brought against our facilities;

·our legal responsibility to minority owners of our surgery centers, which may conflict with our interests and prevent us from acting solely in our best interests;

·potential write-off of all or a portion of intangible assets; and

·potential liabilities relating to the tax deductibility of goodwill.

19

Item. 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

Overview

We acquire, develop and operate ambulatory surgery centers, or centers or ASCs, in partnership with physicians.  As of March 31, 2013, we had 241 operating ASCs, of which we owned a majority interest (primarily 51%) in 234 ASCs and owned a minority interest in seven ASCs (three of which are consolidated). The following table presents the number of procedures performed at our continuing centers and changes in the number of ASCs in operation, under development and under letter of intent for the three months ended March 31, 2013 and 2012.  An ASC is deemed to be under development when a limited partnership or limited liability company has been formed with the physician partners to develop the ASC.

	Three Months Ended
	March 31,
	2013	2012
Procedures	394,313	379,454
Continuing centers in operation, end of period (consolidated)	237	223
Continuing centers in operation, end of period (unconsolidated)	4	2
Average number of continuing centers in operation, during period	238	222
New centers added during period	1	1
Centers discontinued during period	-	2
Centers under development, end of period	-	1
Centers under letter of intent, end of period	4	1

Of the continuing centers in operation at March 31, 2013, 149 centers performed gastrointestinal endoscopy procedures, 49 centers performed procedures in multiple specialties, 36 centers performed ophthalmology procedures and seven centers performed orthopedic procedures.  We intend to expand primarily through the acquisition and development of additional ASCs and through future same-center growth.  During the three months ended March 31, 2013, we experienced a same-center revenue decline of 2% primarily due to two fewer working days during the three months ended March 31, 2013 compared to the same 2012 period.  We expect a 0% to 1% increase in our same-center revenue for 2013, which reflects positive rate adjustments from CMS in 2013 but is offset by a statutory decrease in reimbursement for procedures associated with worker’s compensation claims at our centers in California.  Our same-center revenue guidance also reflects the expected impact of sequestration.  Our growth strategy also includes the acquisition and development of additional surgery centers, which on an annual basis we expect would generate additional operating income of $25 million to $29 million.  We anticipate that because the majority of these acquisitions will occur in the latter part of 2013, their contribution to our 2013 operating income would not be significant. 

While we own less than 100% of each of the entities that own the centers, our consolidated statements of earnings include 100% of the results of operations of each of our consolidated entities, reduced by the noncontrolling partners’ interests share of the net earnings or loss of the surgery center entities.  The noncontrolling ownership interest in each limited partnership or limited liability company is generally held directly or indirectly by physicians who perform procedures at the center.  Our share of the profits and losses of four non-consolidated entities are reported in equity in earnings of unconsolidated affiliates in our consolidated statement of earnings. 

Sources of Revenues

Our revenues are derived from facility fees charged for surgical procedures performed in our surgery centers and, at certain of our surgery centers (primarily centers that perform gastrointestinal endoscopy procedures), charges for anesthesia services provided by medical professionals employed or contracted by our centers.  These fees vary depending on the procedure, but usually include all charges for operating room usage, special equipment usage, supplies, recovery room usage, nursing staff and medications.  Facility fees do not include professional fees charged by the physicians that perform the surgical procedures.  Revenue is recorded at the time of the patient encounter and billings for such procedures are made on or about that same date. At the majority of our centers, it is our policy to collect patient co-payments and deductibles at the time the surgery is performed. Our revenues are recorded net of estimated contractual adjustments from third-party medical service payors. Our billing and accounting systems provide us historical trends of the surgery centers’ cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly for each of our surgery centers as revenue is recognized. Our ability to accurately estimate contractual adjustments is dependent upon and supported by the fact that our surgery centers perform and bill for limited types of procedures, the range of reimbursement for those procedures within each surgery center specialty is very narrow and payments are typically received within 15 to 45 days of billing. These estimates are not, however, established from billing system generated contractual adjustments based on fee schedules for the patient’s insurance plan for each patient encounter.

ASCs depend upon third-party reimbursement programs, including governmental and private insurance programs, to pay for substantially all of the services rendered to patients.  We derived approximately 25% and 27% of our revenues in the three months ended March 31, 2013 and 2012, respectively, from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles.  The Medicare program currently pays ASCs in accordance with predetermined fee schedules.  Our surgery centers are not required to file cost reports and, accordingly, we have no unsettled amounts from governmental third-party payors.

20

Item. 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

ASCs are paid based upon a percentage of the payments to hospital outpatient departments pursuant to the hospital outpatient prospective patient system and reimbursement rates for ASCs are increased annually based on increases in the consumer price index, or CPI.  Effective for fiscal year 2011 and subsequent years, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the Health Reform Law, provides for the annual CPI increases applicable to ASCs to be reduced by a productivity adjustment, which is based on historical nationwide productivity gains.  In 2012, reimbursement rates increased by 1.6%, which we estimate positively impacted our 2012 revenues by approximately $5.0 million and our net earnings per share by $0.05.  The reimbursement rates for 2013 reflect a 0.6% net increase, which we estimate will positively impact our 2013 revenue by approximately $2.5 million and our 2013 earnings per share by $0.02.  There can be no assurance that CMS will not revise the ASC payment system, or that any annual CPI increases will be material.

The Budget Control Act of 2011, or BCA, requires automatic spending reductions of $1.2 trillion for federal fiscal years 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs. The percentage reduction for Medicare may not be more than 2% for a fiscal year, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as "sequestration." Sequestration began on March 1, 2013, and CMS began imposing a 2% reduction on Medicare claims as of April 1, 2013. Unless Congress and the President take action and reach an agreement to change the law, federal spending will be subject to sequestration until the end of federal fiscal year 2021. The full impact of sequestration on our operations is uncertain. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress or whether Congress will attempt to restructure or suspend sequestration. If sequestration continues to be implemented as currently structured, we estimate that the spending reductions will reduce our 2013 revenue and net earnings per share by approximately $5.0 million and $0.05, respectively.

In September 2012, the State of California enacted legislation that reduced the reimbursement rate beginning in 2013 for patients receiving care through the state’s workers’ compensation program.  We estimate that the reduced rates will negatively impact our 2013 earnings per share by approximately $0.06. 

The Health Reform Law represents significant change across the healthcare industry.  The Health Reform Law contains a number of provisions designed to reduce Medicare program spending, including the annual productivity adjustment discussed above that reduces payment updates to ASCs.  However, the Health Reform Law also expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms.  For example, the Health Reform Law expands eligibility under existing Medicaid programs, imposes financial penalties on individuals who fail to carry insurance coverage, creates affordability credits for those not enrolled in an employer-sponsored health plan, requires establishment of, or participation in, a health insurance exchange for each state and permits states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid.  The Health Reform Law also establishes a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates, and increased dependent coverage. 

Many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies.  Medicare must now also cover these preventive services without cost-sharing, and, beginning in 2013, states that provide Medicaid coverage of these preventive services without cost-sharing will receive a one percentage point increase in their federal medical assistance percentage for these services.

Health insurance market reforms that expand insurance coverage may result in an increased volume for certain procedures at our centers.  However, many of these provisions of the Health Reform Law will not become effective until 2014 or later, and these provisions may be amended or repealed or their impact could be offset by reductions in reimbursement under the Medicare program.  On June 28, 2012, the United States Supreme Court upheld the constitutionality of the Health Reform Law except for provisions that would have allowed the Department of Health and Human Services, or HHS, to penalize states that do not implement the Medicaid expansion provisions of the law with the loss of existing federal Medicaid funding.  It is unclear how many states will decline to implement the Medicaid expansion and what the resulting impact will be on the number of uninsured individuals.

Because of the many variables involved, including the law’s complexity, lack of implementing definitive regulations or interpretive guidance, gradual implementation, and possible amendment or repeal, we are unable to predict the net effect of the reductions in Medicare spending, the expected increases in revenues from increased procedure volumes, and numerous other provisions in the law that may affect the Company.  We are further unable to foresee how individuals and employers will respond to the choices afforded them by the Health Reform Law.  Thus, we cannot predict the full impact of the Health Reform Law on the Company at this time.

CMS is increasing its administrative audit efforts through the nationwide expansion of the recovery audit contractor, or RAC, program.  RACs are private contractors that conduct post-payment reviews of providers and suppliers that bill Medicare to detect and correct improper payments for services.  The Health Reform Law expands the RAC program’s scope to include Medicaid claims.  In addition to RACs, other contractors, such as Medicaid Integrity Contractors, perform payment audits to identify and correct improper payments.  We could incur costs associated with appealing any alleged overpayments and be required to repay any alleged overpayments identified by these or other administrative audits.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. CMS has promulgated three national coverage determinations that prevent Medicare from paying for certain serious, preventable medical errors performed in any healthcare facility, such as surgery performed on the wrong patient or the wrong site.  Several commercial payors also do not reimburse providers for certain preventable adverse events.  CMS established a

21

Item. 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

quality reporting program for ASCs under which ASCs that fail to report on five quality measures beginning on October 1, 2012 will receive a 2% reduction in reimbursement for calendar year 2014.  As of October 1, 2012, we have implemented programs and procedures at each of our centers to comply with the quality reporting program prescribed by CMS.  Further, as required by the Health Reform Law, HHS reported to Congress on its plan for implementing a value-based purchasing program for ASCs that would tie Medicare payments to quality and efficiency measures.  The Health Reform Law also requires HHS to study whether to expand to ASCs its current policy of not paying additional amounts for care provided to treat conditions acquired during an inpatient hospital stay.

In addition to payment from governmental programs, ASCs derive a significant portion of their revenues from private healthcare insurance plans. These plans include both standard indemnity insurance programs as well as managed care programs, such as PPOs and HMOs.  The strengthening of managed care systems nationally has resulted in substantial competition among providers of surgery center services that contract with these systems.  Exclusion from participation in a managed care network could result in material reductions in patient volume and revenue.  Some of our competitors have greater financial resources and market penetration than we do.  We believe that all payors, both governmental and private, will continue their efforts over the next several years to reduce healthcare costs and that their efforts will generally result in a less stable market for healthcare services. While no assurances can be given concerning the ultimate success of our efforts to contract with healthcare payors, we believe that our position as a low‑cost alternative for certain surgical procedures should enable our surgery centers to compete effectively in the evolving healthcare marketplace.

Critical Accounting Policies

A summary of significant accounting policies is disclosed in our 2012 Annual Report on Form 10-K.  Our critical accounting policies are further described under the caption “Critical Accounting Policies” in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2012 Annual Report on Form 10-K.  There have been no changes in the nature of our critical accounting policies or the application of those policies since December 31, 2012.

Results of Operations

Our revenues are directly related to the number of procedures performed at our centers.  Our overall growth in procedure volume is impacted directly by the increase in the number of surgery centers in operation and the growth in procedure volume at existing centers.  We increase our number of surgery centers through both acquisitions and developments.  Procedure growth at an existing center may result from additional contracts entered into with third-party payors, increased market share of our physician partners, additional physicians utilizing the center and/or scheduling and operating efficiencies gained at the surgery center.  A significant measurement of how much our revenues grow from year to year for existing centers is our same-center revenue percentage.  We define our same-center group each year as those centers that contain full year-to-date operations in both comparable reporting periods, including the expansion of the number of operating centers associated with a limited partnership or limited liability company.  Our 2013 same-center group, comprised of 222 centers and constituting approximately 92% of our total number of centers, had 2% revenue decline during the three months ended March 31, 2013. We expect to have a 0% to 1% increase in our same-center revenue for 2013, which reflects positive rate adjustments from CMS in 2013, but is offset by 1% due to a statutory decrease in reimbursement for procedures associated with worker’s compensation claims at our centers in California.  In addition, the impact of sequestration effective April 1, 2013 is reflected in our 2013 same-center guidance.

Expenses directly and indirectly related to procedures performed at our surgery centers include clinical and administrative salaries and benefits, supply cost and other operating expenses such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense.  The majority of our corporate salary and benefits cost is associated directly with the number of centers we own and manage and tends to grow in proportion to the growth of our centers in operation.  Our centers and corporate offices also incur costs that are more fixed in nature, such as lease expense, legal fees, property taxes, utilities and depreciation and amortization.

Surgery center profits are allocated to our noncontrolling partners in proportion to their individual ownership percentages and reflected in the aggregate as total net earnings attributable to noncontrolling interests and are presented after net earnings.  The noncontrolling partners of our center limited partnerships and limited liability companies typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax.  Each noncontrolling partner shares in the pre-tax earnings of the center of which it is a partner.  Accordingly, net earnings attributable to the noncontrolling interests in each of our center limited partnerships and limited liability companies are generally determined on a pre-tax basis, and pre-tax earnings are presented before net earnings attributable tononcontrolling interests have been subtracted.

Accordingly, the effective tax rate on pre-tax earnings as presented has been reduced to approximately 16.5%.  However, the effective tax rate based on pre-tax earnings attributable to AmSurg Corp. common shareholders, on an annual basis, will remain near the historical percentage of 40%.  We file a consolidated federal income tax return and numerous state income tax returns with varying tax rates.  Our income tax expense reflects the blending of these rates.

Our interest expense results primarily from our borrowings used to fund acquisition and development activity, as well as interest incurred on capital leases.

22

Item. 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

Net earnings from continuing operations attributable to AmSurg Corp. common shareholders are disclosed on the unaudited consolidated statements of earnings.

The following table shows certain statement of earnings items expressed as a percentage of revenues for the three months ended March 31, 2013 and 2012:

			Three Months Ended
			March 31,
			2013	2012
Revenues			100.0%	100.0%
Operating expenses:
	Salaries and benefits		31.3	31.5
	Supply cost		14.5	14.0
	Other operating expenses		20.5	20.6
	Depreciation and amortization		3.1	3.2
		Total operating expenses	69.4	69.3
Gain on deconsolidation			0.9	-
Equity in earnings of unconsolidated affiliates			0.1	0.2
		Operating income	31.6	30.9
Interest expense			2.9	1.9
	Earnings from continuing operations before income taxes		28.7	29.0
Income tax expense			4.7	4.7
	Net earnings from continuing operations, net of income tax		24.0	24.3
Discontinued operations:
	Earnings from operations of discontinued interests in surgery centers, net of income tax		-	0.1
	Loss on disposal of discontinued interests in surgery centers, net of income tax		-	(0.4)
		Net loss from discontinued operations	-	(0.3)
		Net earnings	24.0	24.0
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations		17.1	17.4
	Net earnings from discontinued operations		-	0.1
		Total net earnings attributable to noncontrolling interests	17.1	17.5
		Net earnings attributable to AmSurg Corp. common shareholders	6.9%	6.5%
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax		6.9%	6.8%
	Discontinued operations, net of income tax		-	(0.3)
		Net earnings attributable to AmSurg Corp. common shareholders	6.9%	6.5%

The number of procedures performed in our ASCs increased by 14,859, or 4%, to 394,313, in the three months ended March 31, 2013 from 379,454 in the comparable 2012 period.  Revenues increased $31.2 million, or 14%, to $260.1 million in the three months ended March 31, 2013 from $228.9 million in the comparable 2012 period.  The increase in procedure and revenue growth is primarily attributable to the additional centers acquired in 2012, which contributed $36.3 million of additional revenues in the three months ended March 31, 2013 due to having a full period of operations in 2013.  During the three months ended March 31, 2013, revenue at our 2013 same-center group decreased $4.6 million, reflecting a 2% decrease, primarily as a result of two fewer working days during the three months ended March 31, 2013 over the comparable 2012 period and the reduction in worker’s compensation reimbursement from the State of California.

The percentage increase in revenues in excess of the percentage increase in procedures is due primarily to the centers acquired in the latter half of 2012, the majority of which are multi-specialty centers and which have a higher average net revenue per procedure than the mix of centers we operated during the three months ended March 31, 2012.

23

Item. 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

Salaries and benefits increased by 13% to $81.6 million in the three months ended March 31, 2013 from $72.1 million in the comparable 2012 period.  Salaries and benefits as a percentage of revenues decreased by 20 basis points in the three months ended March 31, 2013, compared to March 31, 2012, primarily due to the centers acquired in the latter half of 2012, which operate with lower staffing costs as a percentage of revenue than the centers owned in 2012.  Staff at newly acquired and developed centers, as well as the additional staffing required at existing centers, resulted in a 14% increase in salaries and benefits at our surgery centers in the three months ended March 31, 2013.  Furthermore, we experienced a 9% increase in salaries and benefits at our corporate offices during the three months ended March 31, 2013 over the comparable 2012 period, due to additional equity compensation expense, additional staff employed to manage the additional centers added and the impact of annual salary adjustments.

Supply cost was $37.6 million in the three months ended March 31, 2013, an increase of $5.5 million, or 17%, over supply cost in the comparable 2012 period.  The increase was primarily the result of additional procedure volume and an increase in our average supply cost per procedure of 12% in the three months ended March 31, 2013.  This increase in our average supply cost per procedure is a result of the acquisition of nine multi-specialty centers in the latter part of 2012, which generally have higher supply cost per procedure than single specialty centers.

Other operating expenses increased $6.1 million, or 13%, to $53.3 million in the three months ended March 31, 2013 from $47.1 million in the comparable 2012 period.  The additional expense in the 2013 period resulted primarily from:

·centers acquired or opened during 2012, which resulted in an increase of $6.3 million in other operating expenses in the three months ended March 31, 2013; and

·a $300,000 decrease in other operating expenses at our 2013 same-center group in the three months ended March 31, 2013.

Depreciation and amortization expense increased $700,000, or 10%, in the three months ended March 31, 2013, primarily as a result of centers acquired during 2012.

We anticipate further increases in operating expenses in 2013, primarily due to additional acquired centers.

During the three months ended March 31, 2013, we contributed a controlling interest in one center in exchange for a noncontrolling interest in an entity that controls the contributed center and one additional center after the completion of the transaction.  As a result of the transaction, we recognized a gain on deconsolidation of approximately $2.2 million.  Such gain was determined based on the difference between the fair value of the retained noncontrolling interest under the new ownership and operating structure and the carrying value of both the tangible and intangible assets of the entity immediately prior to the transaction. 

Interest expense increased $3.3 million, or 77%, to $7.5 million from $4.3 million, in the three months ended March 31, 2013, primarily due to to the issuance in November 2012 of $250.0 million aggregate principal amount of 5.625% senior unsecured notes and a 2% interest rate increase effective November 2012 for our senior secured notes.  The impact of higher interest rates on our senior unsecured notes and senior secured notes was mitigated in part by an amendment to our revolving credit agreement, which lowered the interest rate under our credit agreement by approximately 25 basis points effective June 2012.   See “— Liquidity and Capital Resources.”

We recognized income tax expense of $12.3 million in the three months ended March 31, 2013 compared to $10.8 million in the comparable 2012 period.  Our effective tax rate in 2013 was 16.5% of earnings from continuing operations before income taxes.  This differs from the federal statutory income tax rate of 35.0% primarily due to the exclusion of the noncontrolling interests’ share of pre-tax earnings and the impact of state income taxes.  Because we deduct goodwill amortization for tax purposes only, more than 60% of our income tax expense is deferred and our deferred tax liability continues to increase, which would only be due in part or in whole upon the disposition of a portion or all of our surgery centers.

During the three months ended March 31, 2012, we classified two additional surgery centers in discontinued operations, of which one center was sold and one was closed during the period.  We pursued the disposition of these centers due to our assessment of their limited growth opportunities.  These centers’ results of operations and gains and losses associated with their dispositions have been classified as discontinued operations in all periods presented.  We recognized an after-tax loss on the disposition of discontinued interests in surgery centers of $893,000 during the three months ended March 31, 2012.  The net earnings derived from the operations of the discontinued surgery centers was $306,000 during the three months ended March 31, 2012.

Noncontrolling interests in net earnings for the three months ended March 31, 2013 increased $4.3 million, or 11%, from the comparable 2012 period, primarily as a result of noncontrolling interests in earnings at surgery centers recently added to operations.  As a percentage of revenues, noncontrolling interests decreased to 17.1% from 17.5% in the three months ended March 31, 2013 as a result of the Company’s higher ownership percentage in recently acquired centers.  The net earnings from discontinued operations attributable to noncontrolling interests was $191,000 during the three months ended March 31, 2012.

Liquidity and Capital Resources

Cash and cash equivalents at March 31, 2013 and 2012 were $42.4 million and $44.3million, respectively.  At March 31, 2013, we had working capital of $115.2 million, compared to $107.8 million at December 31, 2012.  Operating activities for the three months ended March 31, 2013 generated $73.9 million in cash flow from operations, compared to $69.1 million in the three months ended March 31, 2012.  The increase in operating cash flow resulted primarily from higher net earnings in the 2013 period over the comparable 2012 period.  Positive operating cash flows of

24

Item. 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations – (continued)

individual centers are the sole source of cash used to make distributions to our wholly-owned subsidiaries, as well as to our physician partners, which we are obligated to make on a monthly basis in accordance with each partnership’s partnership or operating agreement.  Distributions to noncontrolling interests, which is considered a financing activity, in the three months ended March 31, 2013 and 2012 were $43.9 million and $39.0 million, respectively.  Distributions to noncontrolling interests increased $4.9 million, primarily as a result of additional centers in operation.

The principal source of our operating cash flow is the collection of accounts receivable from governmental payors, commercial payors and individuals.  Each of our surgery centers bills for services as delivered, usually within a few days following the date of the procedure.  Generally, unpaid amounts that are 30 days past due are rebilled based on a standard set of procedures.  If amounts remain uncollected after 60 days, our surgery centers proceed with a series of late-notice notifications until amounts are either collected, contractually written off in accordance with contracted rates or determined to be uncollectible, typically after 90 to 120 days.  Receivables determined to be uncollectible are written off and such amounts are applied to our estimate of allowance for bad debts as previously established in accordance with our policy for bad debt expense.  The amount of actual write-offs of account balances for each of our surgery centers is continuously compared to established allowances for bad debt to ensure thatsuch allowances are adequate.  At March 31, 2013 and 2012, our net accounts receivable represented 36 and 35 days of revenue outstanding, respectively.  The increase in our days outstanding is primarily due to the addition of nine multi-specialty centers during the latter half of 2012, which typically experience slightly longer collection cycles than single-specialty centers.

During the three months ended March 31, 2013, we had total acquisition and capital expenditures of $6.4million, which included:

·$300,000  for the acquisition of interests in ASCs and related transactions; and

·$6.1 million for new or replacement property at existing centers.

At March 31, 2013, we had unfunded construction and equipment purchase commitments for centers under development or under renovation of approximately $4.2 million, which we intend to fund through additional borrowings of long-term debt, operating cash flow and capital contributions by our partners.  During the three months ended March 31, 2013, we received $200,000 in capital contributions by our partners.

At December 31, 2012, we had a contingent purchase price obligation of $2.7 million related to our acquisition of 17 centers from National Surgical Care, Inc. (“NSC”) on September 1, 2011.  During the three months ended March 31, 2013, we paid $2.7 million to NSC as final settlement of such obligation.

On June 29, 2012, we amended our revolving credit agreement which we utilize to, among other things, finance our acquisition and development projects and stock repurchase programs.  As a result of the amendment, the availability under the credit agreement was increased $25.0 million to $475.0 million; the maturity date was extended from April 2016 to June 2017; and the interest rate spread on our LIBOR option was reduced to LIBOR plus 1.50% to 2.25% from LIBOR plus 1.75% to 2.75%.  On November 7, 2012 we further amended our revolving credit agreement and amended the note purchase agreement relating to our senior secured notes to allow for our issuance of the senior unsecured notes (discussed below) and revise certain existing covenants. In connection with the amendment of the note purchase agreement relating to our senior secured notes, the interest rate on our senior secured notes increased to 8.04% from 6.04%.  At March 31, 2013, we had $207.2 million available under our revolving credit agreement. 

On November 20, 2012, we completed a private offering of $250.0 million aggregate principle amount of 5.625% senior unsecured notes due 2020.  The net proceeds from the issuance of the senior unsecured notes were used to pay down a portion of the outstanding obligations on our credit facility.  The senior unsecured notes are pari passu in right of payment with our existing and future senior debt and senior to our existing and future subordinated debt.  Interest accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30^th and November 30^th, beginning on May 30, 2013 and maturing on November 30, 2020. The senior unsecured notes contain certain covenants which, among other things, limit our ability to enter into or guarantee additional borrowing, sell preferred stock, pay dividends and repurchase stock, in each case subject to certain exceptions.

During the three months ended March 31, 2013, we had net repayments on long-term debt of $17.3 million.  At March 31, 2013, we had $267.2 million outstanding under our revolving credit agreement, $250.0 million outstanding pursuant to our senior unsecured notes and $75.0 million outstanding pursuant to our senior secured notes.  We were in compliance with all covenants contained in our revolving credit agreement, the note purchase agreement governing our senior secured notes and the indentures governing our senior unsecured notes. 

During the three months ended March 31, 2013, we received approximately $5.7 million from the exercise of stock options under our employee stock incentive plans.  The tax benefit received from the exercise of those options was approximately $300,000. 

On April 24, 2012, our Board of Directors approved a stock repurchase program for up to $40.0 million of our shares of common stock through November 1, 2013.  We intend to fund the purchase price for shares acquired under the plan using cash generated from the proceeds received when employees exercise stock options, cash generated from our operations or borrowings under our revolving credit facility.  During the three months ended March 31, 2013, we repurchased 438,668 shares for $13.9 million in order to mitigate the dilutive effect of shares issued pursuant to stock option exercises during the recent quarters.  In addition, we repurchased 89,788 shares with a value of approximately $2.8 million to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements.

25

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.  We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates.  Our variable debt instruments are primarily indexed to the prime rate or LIBOR.  Interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements.  Based upon our indebtedness at March 31, 2013, a 100 basis point interest rate change would impact our net earnings and cash flow by approximately $1.6 million annually.  Although there can be no assurances that interest rates willnot change significantly, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2013.

Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our chief executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of March 31, 2013.  Based on that evaluation, our chief executive officer (principal executive officer) and chief financial officer (principal accounting officer) have concluded that our disclosure controls and procedures are effective to allow timely decisions regarding disclosure of material information required to be included in our periodic reports.

Changes in Internal Control Over Financial Reporting

During the period covered by this report, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

26

Part II

Item 1.        Legal Proceedings

                    Not applicable.

Item 1A.     Risk Factors

                    Not applicable.

Item 2.        Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities
								(d) Maximum Number
		(a) Total				(c) Total Number of		(or Approximate Dollar
		Number of			(b) Average	Shares (or Units)		Value) of Shares (or
		Shares			Price Paid	Purchased as Part of		Units) That May Yet
		(or Units)			per Share	Publicly Announced		Be Purchased Under
Period		Purchased			(or Unit)	Plans or Programs		the Plans or Programs
January 1, 2013 through
	January 31, 2013	59,968	(1)	$	31.35	-	$	29,729,939	(2)
February 1, 2013 through
	February 28, 2013	27,085	(1)		31.23	-		29,729,939	(2)
March 1, 2013 through
	March 31, 2013	441,403	(1)		31.77	438,668		15,786,894	(2)
	Total	528,456		$	31.69	438,668	$	15,786,894

(1)	During the first quarter of 2013, we repurchased 89,788 shares of common stock to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the terms of the restricted stock agreements.
(2)	On April 24, 2012, we announced that our board of directors had authorized a stock repurchase program, allowing for the purchase of up to $40,000,000 of our outstanding common stock over an 18 month period.

Item 3.        Defaults Upon Senior Securities

                    Not applicable.

Item 4.        Mine Safety Disclosures

Not applicable.

Item 5.        Other Information

Not applicable.

Item 6.        Exhibits

Exhibits

31.1Certification of President and Chief Executive Officer pursuant to Rule 13a-14(a)

31.2Certification of Executive Vice President and Chief Financial Officer pursuant to Rule 13a-14(a)

32.1     Section 1350 Certification

101      Interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Consolidated Balance Sheets at March 31, 2013 and December 31, 2012, (ii) the Consolidated Statements of Earnings and Comprehensive Income for the three month periods ended March 31, 2013 and 2012, (iii) the Consolidated Statements of Changes in Equity for the three month periods ended March 31, 2013 and 2012, (iv) the Consolidated Statements of Cash Flows for the three month periods ended March 31, 2013 and 2012 and (v) the notes to the Unaudited Consolidated Financial Statements for the three month periods ended March 31, 2013 and 2012.

27

Signature

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMSURG CORP.
Date:  May 7, 2013
	By:	/s/ Claire M. Gulmi
		Claire M. Gulmi
		Executive Vice President and
		Chief Financial Officer
		(Principal Financial and Duly Authorized Officer)

28

EX-31.1

 

Exhibit 31.1

Certifications

I, Christopher A. Holden, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of AmSurg Corp.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:   May 7, 2013

By:	/s/ Christopher A. Holden
Name:	Christopher A. Holden
Title:	President and Chief Executive Officer

EX-31.2

 

Exhibit 31.2

Certifications

I, Claire M. Gulmi, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of AmSurg Corp.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:   May 7, 2013

By:	/s/ Claire M. Gulmi
Name:	Claire M. Gulmi
Title:	Executive Vice President and Chief Financial Officer

EX-32

 

Exhibit 32.1

AMSURG CORP.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AmSurg Corp. (the “Company”) on Form 10-Q for the period ending March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Christopher A. Holden

Christopher A. Holden

President and Chief Executive

Officer of the Company

May 7, 2013

/s/ Claire M. Gulmi

Claire M. Gulmi

Executive Vice President and

Chief Financial Officer of the Company

May 7, 2013

XML

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Goodwill And Intangible Assets
Balance, beginning of period	$ 1,652,002	$ 1,229,298
Goodwill acquired, including post acquisition adjustments	(2,702)	11,911
Disposals	(2,120)	(787)
Balance, end of period	$ 1,647,180	$ 1,240,422

XML

Guarantor (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Condensed Consolidating Financial Information
Unsecured Debt	$ 250,000	$ 250,000

XML

Shareholders' Equity (Share-Based Activity) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Shareholders' Equity
Share-based compensation expense	$ 2,050	$ 1,792
Fair value of shares vested	9,182	5,948
Cash received from option exercises	5,691	2,521
Tax benefit from option exercises	$ 288	$ 79

XML

Guarantor (Balance Sheets) (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 42,413,000	$ 46,398,000	$ 44,320,000	$ 40,718,000
Accounts receivable, Net	101,503,000	96,752,000
Supplies inventory	18,106,000	18,406,000
Deferred income taxes	978,000	3,088,000
Prepaid and other current assets	30,142,000	27,537,000
Total current assets	193,142,000	192,181,000
Property and equipment, net	163,189,000	166,612,000
Investments in unconsolidated affiliates	16,876,000	11,274,000
Total assets	2,042,372,000	2,044,586,000
Liabilities and Equity
Current portion of long-term debt	19,942,000	17,407,000
Total current liabilities	77,934,000	84,413,000
Long-term debt	603,409,000	620,705,000
Deferred income taxes	147,125,000	137,648,000
Other long-term liabilities	26,677,000	25,972,000
Noncontrolling interests - redeemable	175,709,000	175,382,000
Equity:
Total AmSurg Corp. equity	698,964,000	689,488,000
Noncontrolling interests - non-redeemable	312,554,000	310,978,000
Total equity	1,011,518,000	1,000,466,000
Total liabilities and equity	2,042,372,000	2,044,586,000
Parent Company [Member]
Assets
Cash and cash equivalents	4,763,000	7,259,000	8,807,000	8,530,000
Accounts receivable, Net	0	0
Supplies inventory	0	0
Deferred income taxes	978,000	3,088,000
Prepaid and other current assets	23,249,000	19,342,000
Total current assets	28,990,000	29,689,000
Property and equipment, net	9,266,000	9,199,000
Investments in unconsolidated affiliates	1,414,727,000	1,413,061,000
Goodwill and other intangible assets, net	20,837,000	21,311,000
Total assets	1,473,820,000	1,473,260,000
Liabilities and Equity
Current portion of long-term debt	8,629,000	5,357,000
Accounts payable	1,024,000	1,379,000
Other accrued liabilities	23,820,000	29,380,000
Total current liabilities	33,473,000	36,116,000
Long-term debt	583,571,000	599,423,000
Deferred income taxes	147,125,000	137,648,000
Other long-term liabilities	10,687,000	10,585,000
Noncontrolling interests - redeemable	0	0
Equity:
Total AmSurg Corp. equity	698,964,000	689,488,000
Noncontrolling interests - non-redeemable	0	0
Total equity	698,964,000	689,488,000
Total liabilities and equity	1,473,820,000	1,473,260,000
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, Net	0	0
Supplies inventory	0	0
Deferred income taxes	0	0
Prepaid and other current assets	0	0
Total current assets	0	0
Property and equipment, net	0	0
Investments in unconsolidated affiliates	1,383,795,000	1,381,596,000
Goodwill and other intangible assets, net	0	0
Total assets	1,383,795,000	1,381,596,000
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt	0	0
Deferred income taxes	0	0
Other long-term liabilities	0	0
Noncontrolling interests - redeemable	0	0
Equity:
Total AmSurg Corp. equity	1,383,795,000	1,381,596,000
Noncontrolling interests - non-redeemable	0	0
Total equity	1,383,795,000	1,381,596,000
Total liabilities and equity	1,383,795,000	1,381,596,000
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	37,650,000	39,139,000	35,513,000	32,188,000
Accounts receivable, Net	101,503,000	96,752,000
Supplies inventory	18,106,000	18,406,000
Deferred income taxes	0	0
Prepaid and other current assets	11,838,000	13,160,000
Total current assets	169,097,000	167,457,000
Property and equipment, net	153,923,000	157,413,000
Investments in unconsolidated affiliates	0	0
Goodwill and other intangible assets, net	1,148,000	1,206,000
Total assets	324,168,000	326,076,000
Liabilities and Equity
Current portion of long-term debt	11,313,000	12,050,000
Accounts payable	22,853,000	26,035,000
Other accrued liabilities	15,239,000	15,177,000
Total current liabilities	49,405,000	53,262,000
Long-term debt	50,770,000	52,747,000
Deferred income taxes	0	0
Other long-term liabilities	15,990,000	15,387,000
Noncontrolling interests - redeemable	62,250,000	61,939,000
Equity:
Total AmSurg Corp. equity	110,054,000	108,412,000
Noncontrolling interests - non-redeemable	35,699,000	34,329,000
Total equity	145,753,000	142,741,000
Total liabilities and equity	324,168,000	326,076,000
Consolidation, Eliminations [Member]
Assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, Net	0	0
Supplies inventory	0	0
Deferred income taxes	0	0
Prepaid and other current assets	(4,945,000)	(4,965,000)
Total current assets	(4,945,000)	(4,965,000)
Property and equipment, net	0	0
Investments in unconsolidated affiliates	(2,781,646,000)	(2,783,383,000)
Goodwill and other intangible assets, net	1,647,180,000	1,652,002,000
Total assets	(1,139,411,000)	(1,136,346,000)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(4,133,000)	(3,905,000)
Other accrued liabilities	(811,000)	(1,060,000)
Total current liabilities	(4,944,000)	(4,965,000)
Long-term debt	(30,932,000)	(31,465,000)
Deferred income taxes	0	0
Other long-term liabilities	0	0
Noncontrolling interests - redeemable	113,459,000	113,443,000
Equity:
Total AmSurg Corp. equity	(1,493,849,000)	(1,490,008,000)
Noncontrolling interests - non-redeemable	276,855,000	276,649,000
Total equity	(1,216,994,000)	(1,213,359,000)
Total liabilities and equity	(1,139,411,000)	(1,136,346,000)
Consolidated Entities [Member]
Assets
Goodwill and other intangible assets, net	1,669,165,000	1,674,519,000
Liabilities and Equity
Accounts payable	19,744,000	23,509,000
Other accrued liabilities	$ 38,248,000	$ 43,497,000

XML

Fair Value Measurements (Fair Value Of Assets And Liabilities Measured On A Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Fair Value, Inputs, Level 2 [Member]
Supplemental executive retirement savings plan investments - Level 2	$ 11,239	$ 8,804
Fair Value, Inputs, Level 3 [Member]
Contingent purchase price payable - Level 3	$ 0	$ 2,744

XML

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) (Series of Individually Immaterial Business Acquisitions [Member], USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Mar. 31, 2012
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable	$ 0	$ 140
Supplies, inventory, prepaid and other current assets	0	74
Property and equipment	0	786
Goodwill	0	11,911
Accounts payable	0	(11)
Other accrued liabilities	0	(67)
Total fair value	0	12,833
Less: Fair value attributable to noncontrolling interests	0	4,690
Acquisition date fair value of total consideration transferred	$ 0	$ 8,143

XML

Guarantor (Cash Flow Statements) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net cash flows provided by operating activities	$ 73,865	$ 69,145
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(252)	(9,857)
Acquisition of property and equipment	(6,110)	(6,046)
Net cash flows used in investing activities	(6,362)	(15,903)
Cash flows from financing activities:
Proceeds from long-term borrowings	30,870	19,600
Repayment on long-term borrowings	(48,211)	(30,877)
Distributions to noncontrolling interests	(43,914)	(39,009)
Net cash flows provided by (used in) financing activities	(71,488)	(49,640)
Net increase (decrease) in cash and cash equivalents	(3,985)	3,602
Cash and cash equivalents, beginning of period	46,398	40,718
Cash and cash equivalents, end of period	42,413	44,320
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	23,940	10,211
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	0	0
Acquisition of property and equipment	(853)	(751)
Net cash flows used in investing activities	(853)	(751)
Cash flows from financing activities:
Proceeds from long-term borrowings	29,700	19,600
Repayment on long-term borrowings	(45,024)	(28,100)
Distributions to noncontrolling interests	0	0
Changes In Intercompany Balances	533	(460)
Other financing activities, net	(10,792)	(223)
Net cash flows provided by (used in) financing activities	(25,583)	(9,183)
Net increase (decrease) in cash and cash equivalents	(2,496)	277
Cash and cash equivalents, beginning of period	7,259	8,530
Cash and cash equivalents, end of period	4,763	8,807
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	49,577	43,158
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(242)	(9,925)
Acquisition of property and equipment	0	0
Net cash flows used in investing activities	(242)	(9,925)
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0
Repayment on long-term borrowings	0	0
Distributions to noncontrolling interests	(49,486)	(34,042)
Changes In Intercompany Balances	0	0
Other financing activities, net	151	809
Net cash flows provided by (used in) financing activities	(49,335)	(33,233)
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	99,411	92,976
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	0	0
Acquisition of property and equipment	(5,257)	(5,295)
Net cash flows used in investing activities	(5,257)	(5,295)
Cash flows from financing activities:
Proceeds from long-term borrowings	1,170	0
Repayment on long-term borrowings	(3,187)	(2,777)
Distributions to noncontrolling interests	(93,491)	(82,167)
Changes In Intercompany Balances	(533)	460
Other financing activities, net	398	128
Net cash flows provided by (used in) financing activities	(95,643)	(84,356)
Net increase (decrease) in cash and cash equivalents	(1,489)	3,325
Cash and cash equivalents, beginning of period	39,139	32,188
Cash and cash equivalents, end of period	37,650	35,513
Consolidation, Eliminations [Member]
Cash flows from operating activities:
Net cash flows provided by operating activities	(99,063)	(77,200)
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(10)	68
Acquisition of property and equipment	0	0
Net cash flows used in investing activities	(10)	68
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0
Repayment on long-term borrowings	0	0
Distributions to noncontrolling interests	99,063	77,200
Changes In Intercompany Balances	0	0
Other financing activities, net	10	(68)
Net cash flows provided by (used in) financing activities	99,073	77,132
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Consolidated Entities [Member]
Cash flows from financing activities:
Other financing activities, net	$ (10,233)	$ 646

XML

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2013

Fair Value Measurements

Fair Value Of Assets And Liabilities Measured On A Recurring Basis

		March 31,		December 31,
		2013		2012
Assets:
	Supplemental executive retirement savings plan investments - Level 2	$	11,239	$	8,804
Liabilities:
	Contingent purchase price payable - Level 3	$	-	$	2,744

XML

Shareholder's Equity (Schedule of Stock Option Activity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Shareholders' Equity
Outstanding at beginning of period, Number of Shares	1,662,830
Options exercised, Number of Shares	(236,579)
Outstanding at end of period, Number of Shares	1,426,251	1,662,830
Vested or expected to vest at end of period, Number of Shares	1,426,251
Exercisable at end of period, Number of Shares	1,426,251
Outstanding at beginning of period, Weighted Average Exercise Price	$ 23.82
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 24.06
Outstanding at end of period, Weighted Average Exercise Price	$ 23.78	$ 23.82
Exercisable at end of period, Weighted Average Exercise Price	$ 23.78
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term, Period Start	3 years 0 months 0 days	2 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term, Period End	3 years 0 months 0 days	2 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	3 years 0 months 0 days
Vested or expected to vest at end of period, weighted average exercise price	$ 23.78
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	3 years 0 months 0 days

XML

Long-Term Debt (Components Of Long-Term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Long-Term Debt
Revolving credit agreement	$ 267,200	$ 279,780
Senior Unsecured Notes	250,000	250,000
Senior Secured Notes	75,000	75,000
Other debt	19,774	21,350
Capitalized lease arrangements	11,377	11,982
Long-term debt, gross	$ 623,351	$ 638,112

XML

Dispositions (Results Of Operations Of Combined Discontinued Surgery Centers) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Dispositions
Revenues		$ 2,085
Earnings before income taxes		397
Net earnings	$ 0	$ 306

XML

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Shareholders' Equity
Net earnings from continuing operations attributable to AmSurg Corp., Earnings (Numerator)	$ 17,811	$ 15,554
Net earnings attributable to AmSurg Corp., Earnings (Numerator)	$ 17,811	$ 14,776
Net earnings from continuing operations attributable to AmSurg Corp. (Basic), Shares (Denominator)	31,217	30,619
Net earnings from continuing operations attributable to AmSurg Corp. (Diluted), Shares (Denominator)	31,881	31,401
Dilutive Securities, Effect on Basic Earnings Per Share	664	782
Net earnings from continuing operations attributable to AmSurg Corp. per common share (basic), Per Share Amount	$ 0.57	$ 0.51
Net earnings from continuing operations attributable to AmSurg Corp. per common share (diluted), Per Share Amount	$ 0.56	$ 0.50
Net earnings attributable to AmSurg Corp. per common share (Diluted), Per Share Amount	$ 0.56	$ 0.47
Net earnings attributable to AmSurg Corp. per common share (basic), Per Share Amount	$ 0.57	$ 0.48

XML

Shareholder's Equity (Narrative) (Details) (USD $)	0 Months Ended		3 Months Ended
	Apr. 24, 2012 Y	Oct. 20, 2010 Y	Mar. 31, 2013	Mar. 31, 2012
Common Stock:
Stock repurchased program authorized by the board of directors	$ 40,000,000	$ 40,000,000
Period of stock repurchase program, months	18	18
Repurchase of common stock, shares			438,668	61,149
Repurchase of common stock			13,943,000	1,560,000
Average price per share			$ 31.76	$ 25.49
Shares repurchased to cover employee tax withholdings			89,788	48,139
Stock Incentive Plans:
Number of shares authorized for grant under share incentive plan			2,760,250
Shares available for future grants/issuance under stock incentive plan			909,568
Unrecognized compensation cost on non vested awards			$ 12,754,000
Employee Service Share-based Compensation, Nonvested Awards			1 year 3 months 18 days
Share based payment award shares purchased for award			0	75,624
Stock Option or Stock Appreciation Rights [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Options term			10
Restricted Stock [Member]
Stock Incentive Plans:
Shares available for future grants/issuance under stock incentive plan			747,456
Outside Directors [Member] | Restricted Stock [Member] | Period from January 1, 2012 thru current period
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
Outside Directors [Member] | Restricted Stock [Member] | Period prior to January 1, 2012
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Employees [Member] | Restricted Stock [Member] | Period from January 1, 2010 thru current period
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Number of installments in restricted stock granted.			3
Employees [Member] | Restricted Stock [Member] | Period prior to January 1, 2010
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years

XML

Revenue Recognition

3 Months Ended

Mar. 31, 2013

Revenue Recognition

Revenue Recognition

(3) Revenue Recognition

Center revenues consist of billing for the use of the centers' facilities (the “facility fee”) directly to the patient or third-party payor and, atcertain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by our centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians' surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the three months ended March 31, 2013 and 2012, the Company derived approximately 25% and 27%, respectively, of its revenues from governmental healthcare programs, primarily Medicare and Medicare managed programs. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

XML

Long Term Debt (Current & Noncurrent Breakout) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Debt Disclosure Current [Abstract]
Long-term debt	$ 603,409	$ 620,705
Less current portion	19,942	17,407
Long-term debt, gross	$ 623,351	$ 638,112

XML

Basis of Presentation (Details)	Mar. 31, 2013 Centers
Ownership Interests [Line Items]
Number Of Centers Owned Less Than 51 Percent	7
Consolidated [Member]
Ownership Interests [Line Items]
Number Of Centers Owned Less Than 51 Percent	3
Nonconsolidated [Member]
Ownership Interests [Line Items]
Number Of Centers Owned Less Than 51 Percent	4

XML

Guarantor (Tables)

3 Months Ended

Mar. 31, 2013

Condensed Consolidating Financial Information

Condensed Balance Sheet

Consolidating Balance Sheet - March 31, 2013 (Dollars in thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	4,763	$	-	$	37,650	$	-	$	42,413
	Accounts receivable, net				-		-		101,503		-		101,503
	Supplies inventory				-		-		18,106		-		18,106
	Deferred income taxes				978		-		-		-		978
	Prepaid and other current assets				23,249		-		11,838		(4,945)		30,142
		Total current assets			28,990		-		169,097		(4,945)		193,142
Property and equipment, net					9,266		-		153,923		-		163,189
Investments in unconsolidated affiliates and long-term notes receivable					1,414,727		1,383,795		-		(2,781,646)		16,876
Goodwill and other intangible assets, net					20,837		-		1,148		1,647,180		1,669,165
			Total assets	$	1,473,820	$	1,383,795	$	324,168	$	(1,139,411)	$	2,042,372
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	8,629	$	-	$	11,313	$	-	$	19,942
	Accounts payable				1,024		-		22,853		(4,133)		19,744
	Other accrued liabilities				23,820		-		15,239		(811)		38,248
		Total current liabilities			33,473		-		49,405		(4,944)		77,934
Long-term debt					583,571		-		50,770		(30,932)		603,409
Deferred income taxes					147,125		-		-		-		147,125
Other long-term liabilities					10,687		-		15,990		-		26,677
Noncontrolling interests – redeemable					-		-		62,250		113,459		175,709
Equity:
		Total AmSurg Corp. equity			698,964		1,383,795		110,054		(1,493,849)		698,964
		Noncontrolling interests – non-redeemable			-		-		35,699		276,855		312,554
		Total equity			698,964		1,383,795		145,753		(1,216,994)		1,011,518
			Total liabilities and equity	$	1,473,820	$	1,383,795	$	324,168	$	(1,139,411)	$	2,042,372

Consolidating Balance Sheet - December 31, 2012 (Dollars in thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	7,259	$	-	$	39,139	$	-	$	46,398
	Accounts receivable, net				-		-		96,752		-		96,752
	Supplies inventory				-		-		18,406		-		18,406
	Deferred income taxes				3,088		-		-		-		3,088
	Prepaid and other current assets				19,342		-		13,160		(4,965)		27,537
		Total current assets			29,689		-		167,457		(4,965)		192,181
Property and equipment, net					9,199		-		157,413		-		166,612
Investments in unconsolidated affiliates and long-term notes receivable					1,413,061		1,381,596		-		(2,783,383)		11,274
Goodwill and other intangible assets, net					21,311		-		1,206		1,652,002		1,674,519
			Total assets	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	5,357	$	-	$	12,050	$	-	$	17,407
	Accounts payable				1,379		-		26,035		(3,905)		23,509
	Other accrued liabilities				29,380		-		15,177		(1,060)		43,497
		Total current liabilities			36,116		-		53,262		(4,965)		84,413
Long-term debt					599,423		-		52,747		(31,465)		620,705
Deferred income taxes					137,648		-		-		-		137,648
Other long-term liabilities					10,585		-		15,387		-		25,972
Noncontrolling interests – redeemable					-		-		61,939		113,443		175,382
Equity:
		Total AmSurg Corp. equity			689,488		1,381,596		108,412		(1,490,008)		689,488
		Noncontrolling interests – non-redeemable			-		-		34,329		276,649		310,978
		Total equity			689,488		1,381,596		142,741		(1,213,359)		1,000,466
			Total liabilities and equity	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586

Condensed Income Statement

Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2013 (In thousands)
							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues					$	5,380	$	-	$	258,919	$	(4,238)	$	260,061
Operating expenses:
	Salaries and benefits					15,421		-		66,273		(113)		81,581
	Supply cost					-		-		37,644		-		37,644
	Other operating expenses					5,060		-		52,326		(4,125)		53,261
	Depreciation and amortization					772		-		7,310		-		8,082
		Total operating expenses				21,253		-		163,553		(4,238)		180,568
Gain on deconsolidation						2,237		2,237		-		(2,237)		2,237
Equity in earnings of unconsolidated affiliates						50,291		50,291		-		(100,180)		402
		Operating income				36,655		52,528		95,366		(102,417)		82,132
Interest expense						6,923		-		621		-		7,544
	Earnings from continuing operations before income taxes					29,732		52,528		94,745		(102,417)		74,588
Income tax expense						11,921		-		394		-		12,315
	Net earnings from continuing operations					17,811		52,528		94,351		(102,417)		62,273
	Net earnings from discontinued operations					-		-		-		-		-
		Net earnings and comprehensive income				17,811		52,528		94,351		(102,417)		62,273
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		44,462		-		44,462
	Net earnings from discontinued operations					-		-		-		-		-
		Total net earnings attributable to noncontrolling interests				-		-		44,462		-		44,462
			Net earnings and comprehensive income attributable
				to AmSurg Corp. common shareholders	$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811
	Discontinued operations, net of income tax					-		-		-		-		-
			Net earnings and comprehensive income attributable
				to AmSurg Corp. common shareholders	$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811

Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2012 (In thousands)
							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues					$	5,145	$	-	$	227,232	$	(3,478)	$	228,899
Operating expenses:
	Salaries and benefits					14,154		-		58,048		(87)		72,115
	Supply cost					-		-		32,097		-		32,097
	Other operating expenses					4,741		-		45,782		(3,391)		47,132
	Depreciation and amortization					657		-		6,684		-		7,341
		Total operating expenses				19,552		-		142,611		(3,478)		158,685
Equity in earnings of unconsolidated affiliates						44,243		44,243		-		(88,091)		395
		Operating income				29,836		44,243		84,621		(88,091)		70,609
Interest expense						3,709		-		558		-		4,267
	Earnings from continuing operations before income taxes					26,127		44,243		84,063		(88,091)		66,342
Income tax expense						10,396		-		420		-		10,816
	Net earnings from continuing operations					15,731		44,243		83,643		(88,091)		55,526
	Net earnings from discontinued operations					(955)		-		368		-		(587)
		Net earnings and comprehensive income				14,776		44,243		84,011		(88,091)		54,939
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		39,972		-		39,972
	Net earnings from discontinued operations					-		-		191		-		191
		Total net earnings attributable to noncontrolling interests				-		-		40,163		-		40,163
			Net earnings and comprehensive income attributable to
				AmSurg Corp. common shareholders	$	14,776	$	44,243	$	43,848	$	(88,091)	$	14,776
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	15,731	$	44,243	$	43,671	$	(88,091)	$	15,554
	Discontinued operations, net of income tax					(955)		-		177		-		(778)
			Net earnings and comprehensive income attributable to
				AmSurg Corp. common shareholders	$	14,776	$	44,243	$	43,848	$	(88,091)	$	14,776

Condensed Cash Flow Statement

Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2013 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	23,940	$	49,577	$	99,411	$	(99,063)	$	73,865
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(242)		-		(10)		(252)
	Acquisition of property and equipment			(853)		-		(5,257)		-		(6,110)
		Net cash flows used in investing activities		(853)		(242)		(5,257)		(10)		(6,362)
Cash flows from financing activities:
	Proceeds from long-term borrowings			29,700		-		1,170		-		30,870
	Repayment on long-term borrowings			(45,024)		-		(3,187)		-		(48,211)
	Distributions to owners, including noncontrolling interests			-		(49,486)		(93,491)		99,063		(43,914)
	Changes in intercompany balances with affiliates, net			533		-		(533)		-		-
	Other financing activities, net			(10,792)		151		398		10		(10,233)
		Net cash flows provided by (used in) financing activities		(25,583)		(49,335)		(95,643)		99,073		(71,488)
Net increase (decrease) in cash and cash equivalents				(2,496)		-		(1,489)		-		(3,985)
Cash and cash equivalents, beginning of period				7,259		-		39,139		-		46,398
Cash and cash equivalents, end of period			$	4,763	$	-	$	37,650	$	-	$	42,413

Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2012 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	10,211	$	43,158	$	92,976	$	(77,200)	$	69,145
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(9,925)		-		68		(9,857)
	Acquisition of property and equipment			(751)		-		(5,295)		-		(6,046)
		Net cash flows used in investing activities		(751)		(9,925)		(5,295)		68		(15,903)
Cash flows from financing activities:
	Proceeds from long-term borrowings			19,600		-		-		-		19,600
	Repayment on long-term borrowings			(28,100)		-		(2,777)		-		(30,877)
	Distributions to owners, including noncontrolling interests			-		(34,042)		(82,167)		77,200		(39,009)
	Changes in intercompany balances with affiliates, net			(460)		-		460		-		-
	Other financing activities, net			(223)		809		128		(68)		646
		Net cash flows provided by (used in) financing activities		(9,183)		(33,233)		(84,356)		77,132		(49,640)
Net increase (decrease) in cash and cash equivalents				277		-		3,325		-		3,602
Cash and cash equivalents, beginning of period				8,530		-		32,188		-		40,718
Cash and cash equivalents, end of period			$	8,807	$	-	$	35,513	$	-	$	44,320

XML

Guarantor (Income Statements) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Condensed Financial Statements, Captions [Line Items]
Revenues	$ 260,061	$ 228,899
Operating expenses:
Salaries and benefits	81,581	72,115
Supply cost	37,644	32,097
Other operating expenses	53,261	47,132
Depreciation and amortization	8,082	7,341
Total operating expenses	180,568	158,685
Gain (loss) on deconsolidation	2,237	0
Equity in earnings of unconsolidated affiliates	402	395
Operating income	82,132	70,609
Interest expense	7,544	4,267
Earnings from continuing operations before income taxes	74,588	66,342
Income tax expense	12,315	10,816
Net earnings from continuing operations	62,273	55,526
Net earnings (loss) from discontinued operations	0	(587)
Net earnings (loss)	62,273	54,939
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations	44,462	39,972
Net (loss) earnings from discontinued operations	0	191
Total net earnings attributable to noncontrolling interests	44,462	40,163
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,811	14,776
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	17,811	15,554
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	(778)
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,811	14,776
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	5,380	5,145
Operating expenses:
Salaries and benefits	15,421	14,154
Supply cost	0	0
Other operating expenses	5,060	4,741
Depreciation and amortization	772	657
Total operating expenses	21,253	19,552
Gain (loss) on deconsolidation	2,237
Equity in earnings of unconsolidated affiliates	50,291	44,243
Operating income	36,655	29,836
Interest expense	6,923	3,709
Earnings from continuing operations before income taxes	29,732	26,127
Income tax expense	11,921	10,396
Net earnings from continuing operations	17,811	15,731
Net earnings (loss) from discontinued operations	0	(955)
Net earnings (loss)	17,811	14,776
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations	0	0
Net (loss) earnings from discontinued operations	0	0
Total net earnings attributable to noncontrolling interests	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,811	14,776
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	17,811	15,731
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	(955)
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,811	14,776
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	0	0
Operating expenses:
Salaries and benefits	0	0
Supply cost	0	0
Other operating expenses	0	0
Depreciation and amortization	0	0
Total operating expenses	0	0
Gain (loss) on deconsolidation	2,237
Equity in earnings of unconsolidated affiliates	50,291	44,243
Operating income	52,528	44,243
Interest expense	0	0
Earnings from continuing operations before income taxes	52,528	44,243
Income tax expense	0	0
Net earnings from continuing operations	52,528	44,243
Net earnings (loss) from discontinued operations	0	0
Net earnings (loss)	52,528	44,243
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations	0	0
Net (loss) earnings from discontinued operations	0	0
Total net earnings attributable to noncontrolling interests	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	52,528	44,243
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	52,528	44,243
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	52,528	44,243
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	258,919	227,232
Operating expenses:
Salaries and benefits	66,273	58,048
Supply cost	37,644	32,097
Other operating expenses	52,326	45,782
Depreciation and amortization	7,310	6,684
Total operating expenses	163,553	142,611
Gain (loss) on deconsolidation	0
Equity in earnings of unconsolidated affiliates	0	0
Operating income	95,366	84,621
Interest expense	621	558
Earnings from continuing operations before income taxes	94,745	84,063
Income tax expense	394	420
Net earnings from continuing operations	94,351	83,643
Net earnings (loss) from discontinued operations	0	368
Net earnings (loss)	94,351	84,011
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations	44,462	39,972
Net (loss) earnings from discontinued operations	0	191
Total net earnings attributable to noncontrolling interests	44,462	40,163
Net earnings (loss) attributable to AmSurg Corp. common shareholders	49,889	43,848
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	49,889	43,671
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	177
Net earnings (loss) attributable to AmSurg Corp. common shareholders	49,889	43,848
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues	(4,238)	(3,478)
Operating expenses:
Salaries and benefits	(113)	(87)
Supply cost	0	0
Other operating expenses	(4,125)	(3,391)
Depreciation and amortization	0	0
Total operating expenses	(4,238)	(3,478)
Gain (loss) on deconsolidation	(2,237)
Equity in earnings of unconsolidated affiliates	(100,180)	(88,091)
Operating income	(102,417)	(88,091)
Interest expense	0	0
Earnings from continuing operations before income taxes	(102,417)	(88,091)
Income tax expense	0	0
Net earnings from continuing operations	(102,417)	(88,091)
Net earnings (loss) from discontinued operations	0	0
Net earnings (loss)	(102,417)	(88,091)
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations	0	0
Net (loss) earnings from discontinued operations	0	0
Total net earnings attributable to noncontrolling interests	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	(102,417)	(88,091)
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	(102,417)	(88,091)
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	$ (102,417)	$ (88,091)

XML

Long-Term Debt (Redemption Price) (Details) (Unsecured Debt [Member])	Mar. 31, 2013
Period from November 30, 2015 to November 29, 2016
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	104.219%
Period from November 30, 2016 to November 29, 2017
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	102.813%
Period from November 30, 2017 to November 29, 2018
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	101.406%
Period from November 30, 2018 to November 30, 2020
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	100.00%

XML

Use of Estimates (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Use Of Estimates [Abstract]
Allowances for contractual adjustments	$ 281,290,000		$ 216,363,000
Allowances for accounts receivable	24,276,000		22,379,000
Bad debt expense included in other operating expenses	$ 5,914,000	$ 5,183,000

XML

Revenue Recognition (Details)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenue Recognition
Percentage of revenues from governmental healthcare programs	25.00%	27.00%

XML

Use of Estimates

3 Months Ended

Mar. 31, 2013

Use Of Estimates [Abstract]

Use of Estimates

(2) Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The determination of contractual and bad debt allowances constitutes a significant estimate. Some of the factors considered by management in determining the amount of such allowances are the historical trends of the centers' cash collections and contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics. Accordingly, net accounts receivable at March 31, 2013 and December 31, 2012 reflect allowances for contractual adjustments of $281,290,000 and $216,363,000, respectively, and allowances for bad debt expense of $24,276,000 and $22,379,000, respectively.The increase in the allowance for contractual adjustments as of March 31, 2013 is primarily the result of the centers acquired at the end of 2012 and increases in gross fee schedules at certain of the Company's centers.For the three months ended March 31, 2013 and 2012, bad debt expense was approximately $5,914,000 and $5,183,000, respectively, and is included in other operating expenses.

XML

Acquisitions (Narrative) (Details) (USD $)	3 Months Ended			3 Months Ended				0 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Mar. 31, 2013 Minimum [Member]	Mar. 31, 2013 Maximum [Member]	Mar. 31, 2013 Noncontrolling Interest Number Of Centers [Member] Centers	Mar. 31, 2012 Controlling Interest [Member] Centers	Sep. 01, 2011 Acquired Nsc Centers [Member] Centers	Mar. 31, 2013 Acquired Nsc Centers [Member]	Dec. 31, 2012 Acquired Nsc Centers [Member]	Mar. 31, 2013 Current Year Acquisitions [Member]
Business Acquisition [Line Items]
Equity Method Investments	$ 16,876,000		$ 11,274,000								$ 5,201,000
Gain (loss) on deconsolidation	2,237,000	0
Estimated Probability Of Fair Value Variables Range				5.00%	30.00%
Number of business acquisitions						1	2	17
Payments to Acquire Businesses, Net of Cash Acquired	252,000	9,857,000
Purchase Price Payable Commitment										2,744,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High								7,500,000
Contingent Purchase Price Obligation, Settlement Amount	2,744,000								2,744,000
Goodwill deductible for tax purposes	0	7,579,000
Other operating expenses in acquisition related costs, primarily attorney fees	$ 35,000	$ 52,000

XML

Goodwill And Intangible Assets (Summary Of Amortizable Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 17,984	$ 17,971
Accumulated Amortization	(5,824)	(5,279)
Net	12,160	12,692
Deferred Financing Cost [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	14,536	14,523
Accumulated Amortization	(3,519)	(3,029)
Net	11,017	11,494
Customer And Non Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,448	3,448
Accumulated Amortization	(2,305)	(2,250)
Net	$ 1,143	$ 1,198

XML

Supplemental Cash Flow Information (Summary Of Supplemental Cash Flow Information) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash Paid During The Period For
Interest	$ 3,547	$ 6,204
Income taxes, net of refunds	69	1,778
Noncash Investing and Financing Activities
Increase (decrease) in accounts payable associated with acquisition of property and equipment	(675)	(392)
Capital lease obligations	0	120
Effect Of Acquisitions And Related Transactions [Abstract]
Assets acquired, net of cash and adjustments	0	12,911
Liabilities assumed and noncontrolling interests	$ 0	$ (4,768)

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Assets
Cash and cash equivalents	$ 42,413	$ 46,398
Accounts receivable, Net	101,503	96,752
Supplies inventory	18,106	18,406
Deferred income taxes	978	3,088
Prepaid and other current assets	30,142	27,537
Total current assets	193,142	192,181
Property and equipment, net	163,189	166,612
Investments in unconsolidated affiliates	16,876	11,274
Goodwill	1,647,180	1,652,002
Intangible assets, net	21,985	22,517
Total assets	2,042,372	2,044,586
Liabilities and Equity
Current portion of long-term debt	19,942	17,407
Accounts payable	19,744	23,509
Accrued salaries and benefits	23,011	29,251
Other accrued liabilities	15,237	14,246
Total current liabilities	77,934	84,413
Long-term debt	603,409	620,705
Deferred income taxes	147,125	137,648
Other long-term liabilities	26,677	25,972
Noncontrolling interests - redeemable	175,709	175,382
Preferred stock, no par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Equity:
Common stock, no par value, 70,000,000 shares authorized	175,532	183,867
Retained earnings	523,432	505,621
Total AmSurg Corp. equity	698,964	689,488
Noncontrolling interests - non-redeemable	312,554	310,978
Total equity	1,011,518	1,000,466
Total liabilities and equity	$ 2,042,372	$ 2,044,586

XML

Fair Value Measurements (Narrative) (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Fair Value Measurements
Business Acquisition, Preacquisition Contingency, Amount of Settlement	$ 2,744,000
Debt Instrument [Line Items]
Long-term Debt gross	623,351,000	638,112,000
Fixed Interest Rate [Member]
Debt Instrument [Line Items]
Long-term Debt gross	352,403,000
Long-term Debt, Fair Value	371,090,000
Variable Interest Rate [Member]
Debt Instrument [Line Items]
Long-term Debt gross	270,948,000
Long-term Debt, Fair Value	$ 270,948,000

XML

Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net earnings (loss)	$ 62,273	$ 54,939
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	8,082	7,341
Net (gain) loss on sale of long-lived assets	0	599
Gain (loss) on deconsolidation	(2,237)	0
Share-based compensation	2,050	1,792
Excess tax benefit from share-based compensation	(288)	(79)
Deferred income taxes	12,929	8,722
Equity in earnings of unconsolidated affiliates, net	(402)	(395)
Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and dispositions, due to changes in:
Accounts receivable, net	(1,705)	(1,119)
Supplies inventory	(201)	177
Prepaid and other current assets	17	(633)
Accounts payable	(3,040)	(1,693)
Accrued expenses and other liabilities	(4,101)	(985)
Other, net	488	479
Net cash flows provided by operating activities	73,865	69,145
Cash flows from investing activities:
Acquisition of interests in surgery centers and related transactions	(252)	(9,857)
Acquisition of property and equipment	(6,110)	(6,046)
Net cash flows used in investing activities	(6,362)	(15,903)
Cash flows from financing activities:
Proceeds from long-term borrowings	30,870	19,600
Repayment on long-term borrowings	(48,211)	(30,877)
Distributions to noncontrolling interests	(43,914)	(39,009)
Proceeds from issuance of common stock upon exercise of stock options	5,691	2,521
Repurchase of common stock	(16,758)	(2,823)
Capital contributions and ownership transactions by noncontrolling interests	559	869
Excess tax benefit from share-based compensation	288	79
Financing cost incurred	(13)	0
Net cash flows provided by (used in) financing activities	(71,488)	(49,640)
Net increase (decrease) in cash and cash equivalents	(3,985)	3,602
Cash and cash equivalents, beginning of period	46,398	40,718
Cash and cash equivalents, end of period	$ 42,413	$ 44,320

XML

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Acquisitions
Revenues	$ 260,061	$ 268,598
Net earnings	62,273	65,160
Amounts Attributable To Common Shareholders
Net earnings from continuing operations	17,811	18,299
Net earnings	$ 17,811	$ 17,521
Net earnings from continuing operations per common share: Basic	$ 0.57	$ 0.60
Net earnings from continuing operations per common share: Diluted	$ 0.56	$ 0.58
Net earnings: Basic	$ 0.57	$ 0.57
Net earnings: Diluted	$ 0.56	$ 0.56
Weighted average number of shares and share equivalents: Basic	31,217	30,619
Weighted average number of shares and share equivalents: Diluted	31,881	31,401

XML

Dispositions (Tables)

3 Months Ended

Mar. 31, 2013

Dispositions

Results Of Operations Of Centers Discontinued

	Three
	Months Ended
	March 31,
	2012
Net loss from discontinued operations	$	(587)
Net loss from discontinued operations attributable to AmSurg Corp.		(778)

Results Of Operations Of Combined Discontinued Surgery Centers

	Three
	Months Ended
	March 31,
	2012
Revenues	$	2,085
Earnings before income taxes		397
Net earnings		306

XML

Dispositions (Results Of Operations Of Centers Discontinued) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Dispositions
Net earnings (loss) from discontinued operations	$ 0	$ (587)
Discontinued operations, net of income tax, attributable to AmSurg Corp.	$ 0	$ (778)

XML

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2013

Long-Term Debt

Components Of Long-Term Debt

		March 31,		December 31,
		2013		2012
Revolving credit agreement		$	267,200	$	279,780
Senior Unsecured Notes			250,000		250,000
Senior Secured Notes			75,000		75,000
Other debt			19,774		21,350
Capitalized lease arrangements			11,377		11,982
			623,351		638,112
Less current portion			19,942		17,407
	Long-term debt	$	603,409	$	620,705

Redemption Price Percentage

Period	Redemption Price
2015	104.219%
2016	102.813%
2017	101.406%
2018 and thereafter	100.000%

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2013

Basis of Presentation

Basis of Presentation

(1) Basis of Presentation

AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”).The Company does not have an ownership interest in a limited partnership or LLC greater than 51% which it does not consolidate. The Company does have an ownership interest of less than 51% in sevenlimited partnerships and LLCs, three of which it consolidates as the Company has substantive participation rights and four of which it does not consolidate as the Company's rights are limited to protective rights only.The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated limited partnerships and LLCs. Consolidation of such limited partnerships and LLCs is necessary as the Company's wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the limited partnerships and LLCs, and have control of the entities. The responsibilities of the Company's noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. All limited partnerships and LLCs and noncontrolling partners are referred to herein as partnerships and partners, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the face of the consolidated statements of income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows.

As further described in note 11, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company's partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2013, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company's equity and are classified as noncontrolling interests – redeemable on the Company's consolidated balance sheets.

Center profits and losses of consolidated entities are allocated to the Company's partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company's center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company's consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense. In addition, distributions from the partnerships are made to both the Company's wholly owned subsidiaries and the partners on a pre-tax basis.

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwiseconsolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates and long-term notes receivable in the accompanying consolidated balance sheets. The Company's share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanyingconsolidated statement of earnings and comprehensive income. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

The Company operates in one reportable business segment, the ownership and operation of ambulatory surgery centers.

These unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the unaudited interim financial statements contained in this report reflect all adjustments, consisting of only normal recurring accruals, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year.

The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's 2012 Annual Report on Form 10-K.

XML

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Consolidated Balance Sheets
Net of allowance on accounts receivable	$ 24,276	$ 22,379
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	70,000,000	70,000,000
Common stock, shares outstanding	31,898,868	31,941,441

XML

Commitments And Contingencies

3 Months Ended

Mar. 31, 2013

Commitments And Contingencies

Commitments And Contingencies

(11) Commitments and Contingencies

The Company and its subsidiaries are insured with respect to medical malpractice risk on a claims-made basis. The Company also maintains insurance for general liability, director and officer liability and property damage. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Management is not aware of any claims against it or its subsidiaries which would have a material financial impact on the Company.

Certain of the Company's wholly owned subsidiaries, as general partners in the limited partnerships, are responsible for all debts incurred but unpaid by the limited partnerships. As manager of the operations of the limited partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.

In the event of a change in current law that would prohibit the physicians' current form of ownership in the partnerships, the Company would be obligated to purchase the physicians' interests in a substantial majority of the Company's partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2013.

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2013	May 06, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	0000895930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		31,992,677

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 31, 2013

Supplemental Cash Flow Information

Supplemental Cash Flow Information

(12) Supplemental Cash Flow Information

Supplemental cash flow information for the three months ended March 31, 2013 and 2012 is as follows (in thousands):

			Three Months Ended
			March 31,
			2013		2012
Cash paid during the period for:
	Interest		$	3,547	$	6,204
	Income taxes, net of refunds			69		1,778
Non-cash investing and financing activities:
	Decrease in accounts payable associated with acquisition of
		property and equipment		(675)		(392)
	Capital lease obligations			-		120
	Effect of acquisitions and related transactions:
		Assets acquired, net of cash and adjustments		-		12,911
		Liabilities assumed and noncontrolling interests		-		(4,768)

XML

Consolidated Statements Of Earnings (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Consolidated Statements Of Earnings
Revenues	$ 260,061	$ 228,899
Operating expenses:
Salaries and benefits	81,581	72,115
Supply cost	37,644	32,097
Other operating expenses	53,261	47,132
Depreciation and amortization	8,082	7,341
Total operating expenses	180,568	158,685
Gain (loss) on deconsolidation	2,237	0
Equity in earnings of unconsolidated affiliates	402	395
Operating income	82,132	70,609
Interest expense	7,544	4,267
Earnings from continuing operations before income taxes	74,588	66,342
Income tax expense	12,315	10,816
Net earnings from continuing operations	62,273	55,526
Discontinued operations:
(Loss) earnings from operations of discontinued interests in surgery centers, net of income tax	0	306
Loss on disposal of discontinued interests in surgery centers, net of income tax	0	(893)
Net earnings (loss) from discontinued operations	0	(587)
Net earnings	62,273	54,939
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations	44,462	39,972
Net (loss) earnings from discontinued operations	0	191
Total net earnings attributable to noncontrolling interests	44,462	40,163
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,811	14,776
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	17,811	15,554
Discontinued operations, net of income tax, attributable to AmSurg Corp.	0	(778)
Net earnings (loss) attributable to AmSurg Corp. common shareholders	$ 17,811	$ 14,776
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$ 0.57	$ 0.51
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$ 0	$ (0.03)
Net earnings attributable to AmSurg Corp. common shareholders	$ 0.57	$ 0.48
Earnings per share-diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$ 0.56	$ 0.50
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$ 0	$ (0.02)
Net earnings attributable to AmSurg Corp. common shareholders	$ 0.56	$ 0.47
Weighted average number of shares and share equivalents outstanding:
Basic	31,217	30,619
Diluted	31,881	31,401

XML

Goodwill And Intangible Assets

3 Months Ended

Mar. 31, 2013

Goodwill And Intangible Assets

Goodwill And Intangible Assets

(6) Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2013and 2012are as follows (in thousands):

		Three Months Ended
		March 31,
		2013		2012
Balance, beginning of period		$	1,652,002	$	1,229,298
Goodwill acquired, including post acquisition adjustments			(2,702)		11,911
Goodwill disposed, including impact of deconsolidation transaction			(2,120)		(787)
	Balance, end of period	$	1,647,180	$	1,240,422

Amortizable intangible assets at March 31, 2013and December 31, 2012 consisted of the following (in thousands):

		March 31, 2013						December 31, 2012
		Gross						Gross
		Carrying		Accumulated				Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
Deferred financing cost		$	14,536	$	(3,519)	$	11,017	$	14,523	$	(3,029)	$	11,494
Agreements, contracts and other intangible assets			3,448		(2,305)		1,143		3,448		(2,250)		1,198
	Total amortizable intangible assets	$	17,984	$	(5,824)	$	12,160	$	17,971	$	(5,279)	$	12,692

Amortization of intangible assets for the three months ended March 31, 2013 and 2012 was $545,000 and $314,000, respectively. Estimated amortization of intangible assets for the remainder of 2013 and the following five years and thereafter is $1,753,000, $2,334,000, $2,333,000, $2,332,000, $1,514,000, $939,000 and $955,000, respectively. The Company expects to recognize amortization of intangible assets over a weighted average period of 5.6 years.

At March 31, 2013and December 31, 2012, other non-amortizable intangible assets related to restrictive covenant arrangements were $9,825,000, respectively.

XML

Dispositions

3 Months Ended

Mar. 31, 2013

Dispositions

Dispositions

(5) Dispositions

The Company initiated the disposition of certain of its centers during 2012 due to management's assessment of the limited growth opportunities at these centers as a result of certain market driven strategies. Results of operations of the centers discontinued for the three months ended March 31, 2012 are as follows (in thousands):

	Three
	Months Ended
	March 31,
	2012
Net loss from discontinued operations	$	(587)
Net loss from discontinued operations attributable to AmSurg Corp.		(778)

The results of operations of discontinued centers in 2012 have been classified as discontinued operations in the 2012presentation. Results of operations of the discontinued surgery centers for the three months ended March 31, 2012are as follows (in thousands):

	Three
	Months Ended
	March 31,
	2012
Revenues	$	2,085
Earnings before income taxes		397
Net earnings		306

XML

Goodwill And Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2013

Goodwill And Intangible Assets

Changes In Carrying Amount Of Goodwill

		Three Months Ended
		March 31,
		2013		2012
Balance, beginning of period		$	1,652,002	$	1,229,298
Goodwill acquired, including post acquisition adjustments			(2,702)		11,911
Goodwill disposed, including impact of deconsolidation transaction			(2,120)		(787)
	Balance, end of period	$	1,647,180	$	1,240,422

Schedule of Finite-Lived Intangible Assets

		March 31, 2013						December 31, 2012
		Gross						Gross
		Carrying		Accumulated				Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
Deferred financing cost		$	14,536	$	(3,519)	$	11,017	$	14,523	$	(3,029)	$	11,494
Agreements, contracts and other intangible assets			3,448		(2,305)		1,143		3,448		(2,250)		1,198
	Total amortizable intangible assets	$	17,984	$	(5,824)	$	12,160	$	17,971	$	(5,279)	$	12,692

XML

Guarantor

3 Months Ended

Mar. 31, 2013

Condensed Consolidating Financial Information

Condensed Consolidating Financial Information

13. Financial Information for the Company and Its Subsidiaries

In 2012, the Company issued the Senior Unsecured Notes in the aggregate principal amount of $250,000,000. The Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by certain of its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Consolidating Balance Sheet - March 31, 2013 (Dollars in thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	4,763	$	-	$	37,650	$	-	$	42,413
	Accounts receivable, net				-		-		101,503		-		101,503
	Supplies inventory				-		-		18,106		-		18,106
	Deferred income taxes				978		-		-		-		978
	Prepaid and other current assets				23,249		-		11,838		(4,945)		30,142
		Total current assets			28,990		-		169,097		(4,945)		193,142
Property and equipment, net					9,266		-		153,923		-		163,189
Investments in unconsolidated affiliates and long-term notes receivable					1,414,727		1,383,795		-		(2,781,646)		16,876
Goodwill and other intangible assets, net					20,837		-		1,148		1,647,180		1,669,165
			Total assets	$	1,473,820	$	1,383,795	$	324,168	$	(1,139,411)	$	2,042,372
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	8,629	$	-	$	11,313	$	-	$	19,942
	Accounts payable				1,024		-		22,853		(4,133)		19,744
	Other accrued liabilities				23,820		-		15,239		(811)		38,248
		Total current liabilities			33,473		-		49,405		(4,944)		77,934
Long-term debt					583,571		-		50,770		(30,932)		603,409
Deferred income taxes					147,125		-		-		-		147,125
Other long-term liabilities					10,687		-		15,990		-		26,677
Noncontrolling interests – redeemable					-		-		62,250		113,459		175,709
Equity:
		Total AmSurg Corp. equity			698,964		1,383,795		110,054		(1,493,849)		698,964
		Noncontrolling interests – non-redeemable			-		-		35,699		276,855		312,554
		Total equity			698,964		1,383,795		145,753		(1,216,994)		1,011,518
			Total liabilities and equity	$	1,473,820	$	1,383,795	$	324,168	$	(1,139,411)	$	2,042,372

Consolidating Balance Sheet - December 31, 2012 (Dollars in thousands)
						Guarantor		Non-Guarantor		Consolidating		Total
				Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Assets
Current assets:
	Cash and cash equivalents			$	7,259	$	-	$	39,139	$	-	$	46,398
	Accounts receivable, net				-		-		96,752		-		96,752
	Supplies inventory				-		-		18,406		-		18,406
	Deferred income taxes				3,088		-		-		-		3,088
	Prepaid and other current assets				19,342		-		13,160		(4,965)		27,537
		Total current assets			29,689		-		167,457		(4,965)		192,181
Property and equipment, net					9,199		-		157,413		-		166,612
Investments in unconsolidated affiliates and long-term notes receivable					1,413,061		1,381,596		-		(2,783,383)		11,274
Goodwill and other intangible assets, net					21,311		-		1,206		1,652,002		1,674,519
			Total assets	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586
Liabilities and Equity
Current liabilities:
	Current portion of long-term debt			$	5,357	$	-	$	12,050	$	-	$	17,407
	Accounts payable				1,379		-		26,035		(3,905)		23,509
	Other accrued liabilities				29,380		-		15,177		(1,060)		43,497
		Total current liabilities			36,116		-		53,262		(4,965)		84,413
Long-term debt					599,423		-		52,747		(31,465)		620,705
Deferred income taxes					137,648		-		-		-		137,648
Other long-term liabilities					10,585		-		15,387		-		25,972
Noncontrolling interests – redeemable					-		-		61,939		113,443		175,382
Equity:
		Total AmSurg Corp. equity			689,488		1,381,596		108,412		(1,490,008)		689,488
		Noncontrolling interests – non-redeemable			-		-		34,329		276,649		310,978
		Total equity			689,488		1,381,596		142,741		(1,213,359)		1,000,466
			Total liabilities and equity	$	1,473,260	$	1,381,596	$	326,076	$	(1,136,346)	$	2,044,586

Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2013 (In thousands)
							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues					$	5,380	$	-	$	258,919	$	(4,238)	$	260,061
Operating expenses:
	Salaries and benefits					15,421		-		66,273		(113)		81,581
	Supply cost					-		-		37,644		-		37,644
	Other operating expenses					5,060		-		52,326		(4,125)		53,261
	Depreciation and amortization					772		-		7,310		-		8,082
		Total operating expenses				21,253		-		163,553		(4,238)		180,568
Gain on deconsolidation						2,237		2,237		-		(2,237)		2,237
Equity in earnings of unconsolidated affiliates						50,291		50,291		-		(100,180)		402
		Operating income				36,655		52,528		95,366		(102,417)		82,132
Interest expense						6,923		-		621		-		7,544
	Earnings from continuing operations before income taxes					29,732		52,528		94,745		(102,417)		74,588
Income tax expense						11,921		-		394		-		12,315
	Net earnings from continuing operations					17,811		52,528		94,351		(102,417)		62,273
	Net earnings from discontinued operations					-		-		-		-		-
		Net earnings and comprehensive income				17,811		52,528		94,351		(102,417)		62,273
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		44,462		-		44,462
	Net earnings from discontinued operations					-		-		-		-		-
		Total net earnings attributable to noncontrolling interests				-		-		44,462		-		44,462
			Net earnings and comprehensive income attributable
				to AmSurg Corp. common shareholders	$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811
	Discontinued operations, net of income tax					-		-		-		-		-
			Net earnings and comprehensive income attributable
				to AmSurg Corp. common shareholders	$	17,811	$	52,528	$	49,889	$	(102,417)	$	17,811

Consolidating Statement of Earnings and Comprehensive Income - For the Three Months Ended March 31, 2012 (In thousands)
							Guarantor		Non-Guarantor		Consolidating		Total
					Parent Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Revenues					$	5,145	$	-	$	227,232	$	(3,478)	$	228,899
Operating expenses:
	Salaries and benefits					14,154		-		58,048		(87)		72,115
	Supply cost					-		-		32,097		-		32,097
	Other operating expenses					4,741		-		45,782		(3,391)		47,132
	Depreciation and amortization					657		-		6,684		-		7,341
		Total operating expenses				19,552		-		142,611		(3,478)		158,685
Equity in earnings of unconsolidated affiliates						44,243		44,243		-		(88,091)		395
		Operating income				29,836		44,243		84,621		(88,091)		70,609
Interest expense						3,709		-		558		-		4,267
	Earnings from continuing operations before income taxes					26,127		44,243		84,063		(88,091)		66,342
Income tax expense						10,396		-		420		-		10,816
	Net earnings from continuing operations					15,731		44,243		83,643		(88,091)		55,526
	Net earnings from discontinued operations					(955)		-		368		-		(587)
		Net earnings and comprehensive income				14,776		44,243		84,011		(88,091)		54,939
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-		-		39,972		-		39,972
	Net earnings from discontinued operations					-		-		191		-		191
		Total net earnings attributable to noncontrolling interests				-		-		40,163		-		40,163
			Net earnings and comprehensive income attributable to
				AmSurg Corp. common shareholders	$	14,776	$	44,243	$	43,848	$	(88,091)	$	14,776
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	15,731	$	44,243	$	43,671	$	(88,091)	$	15,554
	Discontinued operations, net of income tax					(955)		-		177		-		(778)
			Net earnings and comprehensive income attributable to
				AmSurg Corp. common shareholders	$	14,776	$	44,243	$	43,848	$	(88,091)	$	14,776

Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2013 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	23,940	$	49,577	$	99,411	$	(99,063)	$	73,865
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(242)		-		(10)		(252)
	Acquisition of property and equipment			(853)		-		(5,257)		-		(6,110)
		Net cash flows used in investing activities		(853)		(242)		(5,257)		(10)		(6,362)
Cash flows from financing activities:
	Proceeds from long-term borrowings			29,700		-		1,170		-		30,870
	Repayment on long-term borrowings			(45,024)		-		(3,187)		-		(48,211)
	Distributions to owners, including noncontrolling interests			-		(49,486)		(93,491)		99,063		(43,914)
	Changes in intercompany balances with affiliates, net			533		-		(533)		-		-
	Other financing activities, net			(10,792)		151		398		10		(10,233)
		Net cash flows provided by (used in) financing activities		(25,583)		(49,335)		(95,643)		99,073		(71,488)
Net increase (decrease) in cash and cash equivalents				(2,496)		-		(1,489)		-		(3,985)
Cash and cash equivalents, beginning of period				7,259		-		39,139		-		46,398
Cash and cash equivalents, end of period			$	4,763	$	-	$	37,650	$	-	$	42,413

Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2012 (In thousands)
			Parent		Guarantor		Non-Guarantor		Consolidating		Total
			Issuer		Subsidiaries		Subsidiaries		Adjustments		Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities	$	10,211	$	43,158	$	92,976	$	(77,200)	$	69,145
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions			-		(9,925)		-		68		(9,857)
	Acquisition of property and equipment			(751)		-		(5,295)		-		(6,046)
		Net cash flows used in investing activities		(751)		(9,925)		(5,295)		68		(15,903)
Cash flows from financing activities:
	Proceeds from long-term borrowings			19,600		-		-		-		19,600
	Repayment on long-term borrowings			(28,100)		-		(2,777)		-		(30,877)
	Distributions to owners, including noncontrolling interests			-		(34,042)		(82,167)		77,200		(39,009)
	Changes in intercompany balances with affiliates, net			(460)		-		460		-		-
	Other financing activities, net			(223)		809		128		(68)		646
		Net cash flows provided by (used in) financing activities		(9,183)		(33,233)		(84,356)		77,132		(49,640)
Net increase (decrease) in cash and cash equivalents				277		-		3,325		-		3,602
Cash and cash equivalents, beginning of period				8,530		-		32,188		-		40,718
Cash and cash equivalents, end of period			$	8,807	$	-	$	35,513	$	-	$	44,320

XML

Shareholders' Equity

3 Months Ended

Mar. 31, 2013

Shareholders' Equity

Shareholders' Equity

(9) Shareholders' Equity

a. Common Stock

On October 20, 2010, the Company's Board of Directors authorized a stock repurchase program for up to $40,000,000 of the Company's shares of common stock to be purchased over the following 18 months. On April 24, 2012, the Board of Directors authorized a new stock purchase program for up to $40,000,000 of the Company's shares of common stock through November 1, 2013.

During the three months ended March 31, 2013, the Company purchased 438,668 shares of the Company's common stock for approximately $13,943,000, at an average price of $31.76 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company's stock incentive plans.During the three months ended March 31, 2012, the Company purchased 61,149 shares of the Company's common stock for approximately $1,560,000, at an average price of $25.49 per share. In addition, during the three months ended March 31, 2013, and March 31, 2012, the Companyrepurchased 89,788 sharesand 48,139 shares, respectively, of common stock to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements.

b. Stock Incentive Plans

In May 2006, the Company adopted the AmSurg Corp. 2006 Stock Incentive Plan. The Company also has options outstanding under the AmSurg Corp. 1997 Stock Incentive Plan, under which no additional options may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At March 31, 2013, 2,760,250 shares were authorized for grant under the 2006 Stock Incentive Plan and 909,568 shares were available for future equity grants, including 747,456 shares available for issuance as restricted stock. Restricted stock granted to outside directors prior to 2012 vests over a two year period and restricted stock granted to outside directors in 2012 vest over a one year period. Restricted stock granted to outside directors is subject to certain holding restrictions. Restricted stock granted to employees during 2010 and thereafter vests over four years in three equal installments beginning on the second anniversary of the date of grant. Restricted stock granted to employees prior to 2010 vests at the end of four years from the date of grant. In addition, shares held by the Company's senior management are subject to certain holding restrictions. The fair value of restricted stock is determined based on the closing bid price of the Company's common stock on the grant date.

No options have been issued subsequent to 2008 and all outstanding options are fully vested.Options were granted at market value on the date of the grant and vested over four years.Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity during the three months ended March 31, 2013and 2012 was as follows (in thousands):

	Three Months Ended
	March 31,
	2013		2012
Share-based compensation expense	$	2,050	$	1,792
Fair value of shares vested		9,182		5,948
Cash received from option exercises		5,691		2,521
Tax benefit from option exercises		288		79

As of March 31, 2013, the Company had total unrecognized compensation cost of approximately $12,754,000 related to non-vested awards, which the Company expects to recognize through 2017 and over a weighted average period of 1.3 years.

Average outstanding share-based awards to purchase approximately 75,624 shares of common stock that had an exercise price in excess of the average market price of the common stock during the threemonths ended March 31, 2012, were not included in the calculation of diluted securities options under the treasury method for purposes of determining diluted earnings per share due to their anti-dilutive impact.

A summary of the status of non-vested restricted shares at March 31, 2013 and changes during the three months ended March 31, 2013 is as follows:

			Weighted
		Number	Average
		of	Grant
		Shares	Price
Non-vested shares at December 31, 2012		828,686	$	22.50
	Shares granted	263,140		31.18
	Shares vested	(292,809)		20.59
	Shares forfeited	(13,836)		22.66
Non-vested shares at March 31, 2013		785,181	$	26.12

A summary of stock option activity for the three months ended March 31, 2013 is summarized as follows:

					Weighted
					Average
			Weighted		Remaining
		Number	Average		Contractual
		of	Exercise		Term
		Shares	Price		(in years)
Outstanding at December 31, 2012		1,662,830	$	23.82	2.9
	Options exercised with total intrinsic value of $5,691,000	(236,579)		24.06
Outstanding at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0
Vested at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0
Exercisable at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at March 31, 2013 exercised their options at the Company's closing stock price on March 31, 2013.

c. Earnings per Share

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

			Three Months Ended March 31,
						Per
			Earnings		Shares	Share
			(Numerator)		(Denominator)	Amount
2013:
Net earnings from continuing operations attributable to AmSurg Corp.
	per common share (basic)		$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares				-	664
	Net earnings from continuing operations attributable to AmSurg Corp.
		per common share (diluted)	$	17,811	31,881	$	0.56
Net earnings attributable to AmSurg Corp. per common share (basic)			$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares				-	664
	Net earnings attributable to AmSurg Corp.
		per common share (diluted)	$	17,811	31,881	$	0.56
2012:
Net earnings from continuing operations attributable to AmSurg Corp.
	per common share (basic)		$	15,554	30,619	$	0.51
Effect of dilutive securities options and non-vested shares				-	782
	Net earnings from continuing operations attributable to AmSurg Corp.
		per common share (diluted)	$	15,554	31,401	$	0.50
Net earnings attributable to AmSurg Corp. per common share (basic)			$	14,776	30,619	$	0.48
Effect of dilutive securities options and non-vested shares				-	782
	Net earnings attributable to AmSurg Corp.
		per common share (diluted)	$	14,776	31,401	$	0.47

XML

Long-Term Debt

3 Months Ended

Mar. 31, 2013

Long-Term Debt

Long-Term Debt

(7)Long-term Debt

Long-term debt at March 31, 2013 and December 31, 2012 was comprised of the following (in thousands):

		March 31,		December 31,
		2013		2012
Revolving credit agreement		$	267,200	$	279,780
Senior Unsecured Notes			250,000		250,000
Senior Secured Notes			75,000		75,000
Other debt			19,774		21,350
Capitalized lease arrangements			11,377		11,982
			623,351		638,112
Less current portion			19,942		17,407
	Long-term debt	$	603,409	$	620,705

a.       Credit Facility

On June 29, 2012, the Company amended its revolving credit agreement to increase the borrowing capacity and adjust the interest rate spreads. On November 7, 2012, the Company further amended its revolving credit agreement to allow for the Company's issuance of the 5.625% Senior Unsecured Notes (discussed below), which resulted in certain adjustments to the existing covenants. The revolving credit agreement, as amended, permits the Company to borrow up to $475,000,000 at an interest rate equal to, at the Company's option, the base rate plus 0.50% to 1.25% or LIBOR plus 1.50% to 2.25%, or a combination thereof; provides for a fee of 0.20% to 0.40% of unused commitments; and contains certain covenants relating to the ratio of debt to operating performance measurements, interest coverage ratios and minimum net worth. Borrowings under the revolving credit agreement mature in June 2017 and are secured primarily by a pledge of the stock of our wholly-owned subsidiaries and our partnership and membership interests in the limited partnerships and limited liability companies. The Company was in compliance with the covenants contained in the revolving credit agreement at March 31, 2013.

b.       Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250,000,000 aggregate principal amount of 5.625% senior unsecured notes due 2020 (the “Senior Unsecured Notes”). The net proceeds from the issuance of the Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company's existing revolving credit agreement, creating capacity to fund future acquisitions. The Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by certain of its existing and subsequently acquired or organized wholly owned domestic subsidiaries, (the “Guarantors”). The Senior Unsecured Notes are paripassu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, beginning on May 30, 2013, and ending on the maturity date of November 30, 2020.

Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after November 30, 2015, the Company may redeem the Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:

Period	Redemption Price
2015	104.219%
2016	102.813%
2017	101.406%
2018 and thereafter	100.000%

The Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company's ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the SeniorUnsecured Notes at March 31, 2013.

In connection with the issuance of the Senior Unsecured Notes, the Company entered into a registration rights agreement, dated November 20, 2012 (the “Registration Rights Agreement”). Under the terms of the Registration Rights Agreement, the Company and the Guarantors agreed to use their commercially reasonable efforts to file an exchange offer registration statement with respect to the Senior Unsecured Notes with the Securities and Exchange Commission (the “SEC”) and consummate the exchange offer within 270 days from the date of the Registration Rights Agreement. On May 2, 2013, the registration statement became effective, following which, the holders of the Senior Unsecured Notes have 20 business days to complete their exchange.

c.       Senior Secured Notes

The senior secured notes (the “Senior Secured Notes”) were issued on May 28, 2010, pursuant to a note purchase agreement, in the principal amount of $75,000,000 and are due May 28, 2020. The Senior Secured Notes, which were originally issued with a stated interest rate of 6.04%, were amended on November 7, 2012 to allow for the Company's issuance of the Senior Unsecured Notes, which resulted in an increase in the annual interest rate of 2% to 8.04%, and included certain other adjustments to the existing covenants. The Senior Secured Notes are paripassu with the indebtedness under the Company's revolving credit agreement and the Senior Unsecured Notes and require payment of principal beginning in August 2013. The note purchase agreement governing the Senior Secured Notes contains covenants similar to the covenants in the revolving credit agreement and includes a make whole provision in the event of any prepayment of principle. The Company was in compliance with the covenants contained in the note purchase agreement relating to the Senior Secured Notes at March 31, 2013.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2013

Fair Value Measurements

Fair Value Measurements

(8) Fair Value Measurements

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following fair value hierarchy:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.

Level 3: Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The Company adopted the updated guidance of the Financial Accounting Standards Board(“FASB”) related to fair value measurements and disclosures, which requires a reporting entity to disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and to describe the reasons for the transfers. In addition, in the reconciliation for fair value measurements using significant unobservable inputs, or Level 3, a reporting entity should disclose separately information about purchases, sales, issuances and settlements. The updated guidance also requires that an entity should provide fair value measurement disclosures for each class of assets and liabilities and disclosures about the valuation techniques and inputs used to measure fair value for both recurring and non-recurring fair value measurements for Level 2 and Level 3 fair value measurements. The guidance was effective for the Company January 1, 2010, except for the disclosures about purchases, sales, issuances and settlements in the roll forward activity in Level 3 fair value measurements, which became effective for the Company January 1, 2011. The Company adopted the additional guidance with respect to the roll forward activity in Level 3 fair value measurements on January 1, 2011.

In determining the fair value of assets and liabilities that are measured on a recurring basis atMarch 31, 2013 and December 31, 2012, with the exception of the contingent purchase price payable, the Company utilized Level 2 inputs to perform such measurements methods,which were commensurate with the market approach. The Company utilized Level 3 inputs, which utilizes unobservable data, to measure the fair value of the contingent purchase price payable (in thousands):

		March 31,		December 31,
		2013		2012
Assets:
	Supplemental executive retirement savings plan investments - Level 2	$	11,239	$	8,804
Liabilities:
	Contingent purchase price payable - Level 3	$	-	$	2,744

The fair value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets, was determined using the calculated net asset values obtained from the plan administrator and observable inputs of similar public mutual fund investments. The fair value of the contingent purchase price payable related to the centers acquired from NSC as of December 31, 2012, was determined utilizing the actual earnings of those centers during the earnout period, January 1, 2012 to December 31, 2012, in accordance with the purchase agreement. During the three months ended March 31, 2013, the Company paid $2,744,000 as final settlement of the contingent purchase price payable using its revolving credit facility. There were no transfers to or from Levels 1 and 2 during the three months ended March 31, 2013.

Cash and cash equivalents, receivables and payables are reflected in the financial statements at cost, which approximates fair value. The fair value of fixed rate long-term debt, with a carrying value of $352,403,000, was$371,090,000at March 31, 2013. The fair value of variable rate long-term debt approximates its carrying value of $270,948,000 at March 31, 2013. With the exception of the Company's Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company's Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

XML

Income Taxes

3 Months Ended

Mar. 31, 2013

Income Taxes

Income Taxes

(10) Income Taxes

The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company's policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings and comprehensive income. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file U.S. federal and various state tax returns. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2009.

XML

Acquisitions (Revs and Earnings) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Business Acquisition [Line Items]
Net earnings (loss)	$ 62,273	$ 54,939
Less: Net earnings attributable to noncontrolling interests	44,462	40,163
Net earnings (loss) attributable to AmSurg Corp. common shareholders	17,811	14,776
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Revenues	0	215
Net earnings (loss)	0	74
Less: Net earnings attributable to noncontrolling interests	0	35
Net earnings (loss) attributable to AmSurg Corp. common shareholders	$ 0	$ 39

XML

Shareholder's Equity (Schedule of Stock Option Activity (Parenthetical) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013
Shareholders' Equity
Total intrinsic value with options exercised	$ 5,691,000
Aggregate intrinsic value of options outstanding	14,059,000
Total intrinsic value of options vested or expected to vest	14,059,000
Total Intrinsic value of options exercisable	$ 14,059,000

XML

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2013

Acquisitions

Fair Value Of Total Consideration Transferred And Major Class Of Consideration

		Three Months Ended March 31,
		2013		2012
Accounts receivable		$	-	$	140
Supplies, inventory, prepaid and other current assets			-		74
Property and equipment			-		786
Goodwill			-		11,911
Accounts payable			-		(11)
Other accrued liabilities			-		(67)
	Total fair value		-		12,833
	Less: Fair value attributable to noncontrolling interests		-		4,690
	Acquisition date fair value of total consideration transferred	$	-	$	8,143

Revenues And Net Earnings Associated With Acquisitions

		Three Months Ended March 31,
		2013		2012
Revenues		$	-	$	215
Net earnings			-		74
Less: Net earnings attributable to noncontrolling interests			-		35
	Net earnings attributable to AmSurg Corp. common shareholders	$	-	$	39

Consolidated Pro Forma Results Of Acquisition

			Three Months Ended
			March 31,
			2013		2012
Revenues			$	260,061	$	268,598
Net earnings				62,273		65,160
Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings from continuing operations			17,811		18,299
	Net earnings			17,811		17,521
	Net earnings from continuing operations per common share:
		Basic	$	0.57	$	0.60
		Diluted	$	0.56	$	0.58
	Net earnings:
		Basic	$	0.57	$	0.57
		Diluted	$	0.56	$	0.56
	Weighted average number of shares and share equivalents:
		Basic		31,217		30,619
		Diluted		31,881		31,401

XML

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2013

Shareholders' Equity

Share-Based Activity

	Three Months Ended
	March 31,
	2013		2012
Share-based compensation expense	$	2,050	$	1,792
Fair value of shares vested		9,182		5,948
Cash received from option exercises		5,691		2,521
Tax benefit from option exercises		288		79

Schedule Of Changes In Non-Vested Restricted Shares

			Weighted
		Number	Average
		of	Grant
		Shares	Price
Non-vested shares at December 31, 2012		828,686	$	22.50
	Shares granted	263,140		31.18
	Shares vested	(292,809)		20.59
	Shares forfeited	(13,836)		22.66
Non-vested shares at March 31, 2013		785,181	$	26.12

Schedule Of Stock Option Activity

					Weighted
					Average
			Weighted		Remaining
		Number	Average		Contractual
		of	Exercise		Term
		Shares	Price		(in years)
Outstanding at December 31, 2012		1,662,830	$	23.82	2.9
	Options exercised with total intrinsic value of $5,691,000	(236,579)		24.06
Outstanding at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0
Vested at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0
Exercisable at March 31, 2013 with aggregate intrinsic value of $14,059,000		1,426,251	$	23.78	3.0

Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share

			Three Months Ended March 31,
						Per
			Earnings		Shares	Share
			(Numerator)		(Denominator)	Amount
2013:
Net earnings from continuing operations attributable to AmSurg Corp.
	per common share (basic)		$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares				-	664
	Net earnings from continuing operations attributable to AmSurg Corp.
		per common share (diluted)	$	17,811	31,881	$	0.56
Net earnings attributable to AmSurg Corp. per common share (basic)			$	17,811	31,217	$	0.57
Effect of dilutive securities options and non-vested shares				-	664
	Net earnings attributable to AmSurg Corp.
		per common share (diluted)	$	17,811	31,881	$	0.56
2012:
Net earnings from continuing operations attributable to AmSurg Corp.
	per common share (basic)		$	15,554	30,619	$	0.51
Effect of dilutive securities options and non-vested shares				-	782
	Net earnings from continuing operations attributable to AmSurg Corp.
		per common share (diluted)	$	15,554	31,401	$	0.50
Net earnings attributable to AmSurg Corp. per common share (basic)			$	14,776	30,619	$	0.48
Effect of dilutive securities options and non-vested shares				-	782
	Net earnings attributable to AmSurg Corp.
		per common share (diluted)	$	14,776	31,401	$	0.47

XML

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013
Shareholders' Equity
Non-vested shares at beginning of period, Number of Shares	828,686
Non-vested shares at end of period, Weighted Average Grant Price	$ 22.50
Shares granted, Number of Shares	263,140
Shares granted, Weighted Average Grant Price	$ 31.18
Shares vested, net of shares repurchased to cover tax withholding requirements,, Number of Shares	(292,809)
Shares vested, net of shares repurchased to cover tax withholding requirements, , Weighted Average Grant Price	$ 20.59
Shares forfeited, Number of Shares	(13,836)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 22.66
Non-vested shares at end of period, Number of Shares	785,181
Non-vested shares at end of period, Weighted Average Grant Price	$ 26.12

XML

Long-Term Debt (Narrative) (Details) (USD $)			3 Months Ended		0 Months Ended	3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Line of Credit [Member]	Mar. 31, 2013 Unsecured Debt [Member]	Nov. 07, 2012 Secured Debt [Member]	Mar. 31, 2013 Secured Debt [Member]	Mar. 31, 2013 Maximum [Member] Line of Credit [Member]	Mar. 31, 2013 Minimum [Member] Line of Credit [Member]	Mar. 31, 2013 Period from current report date to November 30, 2015 Unsecured Debt [Member]	Mar. 31, 2013 Period from January 1, 2012 through November 7, 2012 Secured Debt [Member]
Credit Facility
Borrowing capacity of new revolving credit agreement			$ 475,000,000
Line of Credit Facility, Expiration Date			Jun. 01, 2017
Debt instruments interest rate base rate plus							1.25%	0.50%
Debt instruments interest rate Libor plus							2.25%	1.50%
Unused capacity commitment fee, percentage							0.40%	0.20%
Senior Unsecured Debt
Unsecured Debt	250,000,000	250,000,000
Debt Instrument, Interest Rate, Stated Percentage				5.625%		8.04%				6.04%
Debt Instrument, Maturity Date				Nov. 30, 2020		May 28, 2020
Redeemable Principal Percentage				35.00%
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount									105.625%
Senior Secured Debt
Senior Secured Notes	$ 75,000,000	$ 75,000,000
Debt Instrument, Interest Rate, Stated Percentage				5.625%		8.04%				6.04%
Debt Instrument, Maturity Date				Nov. 30, 2020		May 28, 2020
Debt Instrument, Interest Rate Increase					200

XML

Consolidated Statements Of Changes In Equity (USD $)	Total	Common Stock Including Additional Paid in Capital [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
Balance at Dec. 31, 2011		$ 173,187,000	$ 443,058,000	$ 132,222,000	$ 748,467,000	$ 170,636,000
Balance (in shares) at Dec. 31, 2011		31,284,000
Issuance of restricted common stock (in shares)		255,000
Stock options exercised		2,521,000			2,521,000
Stock options exercised (in shares)		111,000
Stock repurchased	(1,560,000)	(2,823,000)			(2,823,000)
Stock repurchased (in shares)	(61,149)	(109,000)
Share-based compensation, value	1,792,000	1,792,000			1,792,000
Tax Benefit from Stock Options Exercised		198,000			198,000
Net earnings	54,939,000		14,776,000	6,062,000	20,838,000	34,101,000
Distributions to noncontrolling interests, net of capital contributions				(6,434,000)	(6,434,000)	(32,546,000)
Sale of noncontrolling interest, value		(1,587,000)		1,728,000	141,000	0
Acquisitions and other transactions impacting noncontrolling interests				2,223,000	2,223,000	2,467,000
Disposals and other transactions impacting noncontrolling interests		(369,000)			(369,000)	176,000
Balance at Mar. 31, 2012		172,919,000	457,834,000	135,801,000	766,554,000	174,834,000
Balance (in shares) at Mar. 31, 2012		31,541,000
Balance at Dec. 31, 2012	1,000,466,000	183,867,000	505,621,000	310,978,000	1,000,466,000	175,382,000
Balance (in shares) at Dec. 31, 2012		31,941,000
Issuance of restricted common stock (in shares)		263,000
Cancellation of restricted common stock (in shares)		(14,000)
Stock options exercised		5,691,000			5,691,000
Stock options exercised (in shares)	236,579	237,000
Stock repurchased	(13,943,000)	(16,758,000)			(16,758,000)
Stock repurchased (in shares)	(438,668)	(528,000)
Share-based compensation, value	2,050,000	2,050,000			2,050,000
Tax Benefit from Stock Options Exercised		1,630,000			1,630,000
Net earnings	62,273,000		17,811,000	12,232,000	30,043,000	32,230,000
Distributions to noncontrolling interests, net of capital contributions				(11,891,000)	(11,891,000)	(31,823,000)
Purchase of noncontrolling interest, value		(304,000)		(133,000)	(437,000)	(316,000)
Sale of noncontrolling interest, value		(644,000)		1,419,000	775,000	236,000
Acquisitions and other transactions impacting noncontrolling interests				266,000	266,000	0
Disposals and other transactions impacting noncontrolling interests		0		(317,000)	(317,000)	0
Balance at Mar. 31, 2013	$ 1,011,518,000	$ 175,532,000	$ 523,432,000	$ 312,554,000	$ 1,011,518,000	$ 175,709,000
Balance (in shares) at Mar. 31, 2013		31,899,000

XML

Acquisitions

3 Months Ended

Mar. 31, 2013

Acquisitions

Acquisitions

(4) Acquisitions and Investments in Unconsolidated Affiliates

As a significant part of its growth strategy, the Company primarily acquires controlling interests in centers. The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.

During the three months ended March 31, 2013, the Company entered into a transaction whereby it contributed cash plus a controlling interest in one center in exchange for a noncontrolling interest in an entity that controls the contributed center and one additional center after the completion of the transaction. Management of the Company believes this structure will provide both economies of scale and potential future growth opportunities in the market. As a result of the transaction, the Company recorded in the accompanying consolidated balance sheets the fair value of the noncontrolling interest in the entity which now controls the contributed centers of approximately $5,201,000 as a component of investments in unconsolidated affiliates and long term notes receivable. The Company also recognized a gain on deconsolidation in the accompanying consolidated statements of earnings and comprehensive income of approximately $2,237,000. Such gain was determined based on the difference between the fair value of the retained noncontrolling interest under the new ownership and operating structure and the carrying value of both the tangible and intangible assets of the entity immediately prior to the transaction. The fair value of the retained noncontrolling interest was based on various estimates of the expected future earnings under likely scenarios which were weighted by the probability of each outcome using a range of expected probability of 5% to 30%.

During the three months ended March 31, 2012,the Company, through a wholly owned subsidiary, acquired a controlling interest in two centers, one of which was merged into an existing center.

The aggregate amount paid for the centers acquired and for settlement of purchase price payable obligations during the three months ended March 31, 2013 and 2012 was approximately $252,000and $9,857,000, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company's revolving credit facility. The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company's business model.

At December 31, 2012, the Company had contingent purchase price obligations of$2,744,000related to the Company's acquisition of 17 centers from National Surgical Care, Inc. (“NSC”) on September 1, 2011. The Company agreed to pay as additional consideration an amount up to $7,500,000 based on a multiple of the excess earnings over the targeted earnings of the acquired centers, if any, from the period of January 1, 2012 to December 31, 2012

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed in the three months ended March 31, 2013 and 2012 are as follows (in thousands):

		Three Months Ended March 31,
		2013		2012
Accounts receivable		$	-	$	140
Supplies, inventory, prepaid and other current assets			-		74
Property and equipment			-		786
Goodwill			-		11,911
Accounts payable			-		(11)
Other accrued liabilities			-		(67)
	Total fair value		-		12,833
	Less: Fair value attributable to noncontrolling interests		-		4,690
	Acquisition date fair value of total consideration transferred	$	-	$	8,143

Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests in centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. For the three months ended March 31, 2013 and 2012, respectively, approximately $0 and $7,579,000 of goodwill recorded was deductible for tax purposes.In connection with the transactions discussed above, the Company incurred and expensed in other operating expenses approximately $35,000 and $52,000 in acquisition related costs, primarily attorney's fees,for the three months ended March 31, 2013and 2012, respectively

Revenues and net earnings included in the three months ended March 31, 2013 and 2012 associated with these acquisitions are as follows (in thousands):

		Three Months Ended March 31,
		2013		2012
Revenues		$	-	$	215
Net earnings			-		74
Less: Net earnings attributable to noncontrolling interests			-		35
	Net earnings attributable to AmSurg Corp. common shareholders	$	-	$	39

The unaudited consolidated pro forma results for the three months ended March 31, 2013 and 2012, assuming all 2013 acquisitions had been consummated on January 1, 2012 and all 2012 acquisitions had been consummated on January 1, 2011, are as follows (in thousands, except per share data):

			Three Months Ended
			March 31,
			2013		2012
Revenues			$	260,061	$	268,598
Net earnings				62,273		65,160
Amounts attributable to AmSurg Corp. common shareholders:
	Net earnings from continuing operations			17,811		18,299
	Net earnings			17,811		17,521
	Net earnings from continuing operations per common share:
		Basic	$	0.57	$	0.60
		Diluted	$	0.56	$	0.58
	Net earnings:
		Basic	$	0.57	$	0.57
		Diluted	$	0.56	$	0.56
	Weighted average number of shares and share equivalents:
		Basic		31,217		30,619
		Diluted		31,881		31,401

XML

Subsequent Events (Details) (USD $)	3 Months Ended
	Mar. 31, 2013 Centers
Aggregate purchase price of surgery centers	$ 11,400,000
Number of business units	1

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 31, 2013

Supplemental Cash Flow Information

Summary Of Supplemental Cash Flow Information

			Three Months Ended
			March 31,
			2013		2012
Cash paid during the period for:
	Interest		$	3,547	$	6,204
	Income taxes, net of refunds			69		1,778
Non-cash investing and financing activities:
	Decrease in accounts payable associated with acquisition of
		property and equipment		(675)		(392)
	Capital lease obligations			-		120
	Effect of acquisitions and related transactions:
		Assets acquired, net of cash and adjustments		-		12,911
		Liabilities assumed and noncontrolling interests		-		(4,768)

XML

Goodwill And Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Goodwill And Intangible Assets
Amortization of Intangible Assets	$ 545,000	$ 314,000
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	1,753,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	2,334,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	2,333,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	2,332,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,514,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	939,000
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	955,000
Finite-Lived Intangible Asset, Useful Life	5 years 7 months 6 days
Restrictive Covenant Agreements	$ 9,825,000		$ 9,825,000

XML

Subsequent Events

3 Months Ended

Mar. 31, 2013

Subsequent Events

Subsequent Events

(14) Subsequent Events

The Company assessed events occurring subsequent to March 31, 2013 for potential recognition and disclosure in the unaudited consolidated financial statements. In April2013, the Company, through a wholly owned subsidiary, acquired a majority interest in a surgery center for a purchase price of approximately $11,400,000. Other than as previously described, no events have occurred that would require adjustment to or disclosure in the unaudited consolidated financial statements.